var title_f24_13_24784="Monocular vision loss";
var content_f24_13_24784=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 606px\">",
"   <div class=\"ttl\">",
"    Monocular vision loss algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 586px; height: 695px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EOM: extraocular movement; IIH: idiopathic intracranial hypertension; IOP: intraocular pressure.",
"     <br>",
"      * Eccentric pupil, prolapse of uvea or other structure, decreased anterior chamber size, and/or tenting of cornea/sclera.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Injuries anterior and posterior to the lens often coexist.",
"       <br>",
"        &Delta; Causes include rapidly expanding infectious, vascular, or neoplastic masses.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_13_24784=[""].join("\n");
var outline_f24_13_24784=null;
var title_f24_13_24785="Recurrent cellulitis";
var content_f24_13_24785=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eczema of the breast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cellulitis of the breast can be a consequence of an overlying skin abnormality such as eczema.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Dixon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_13_24785=[""].join("\n");
var outline_f24_13_24785=null;
var title_f24_13_24786="Spina bifida A";
var content_f24_13_24786=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spina bifida and hydrocephaly (Arnold-Chiari) at 33 postmenstrual weeks and one day",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Longitudinal view showing the large lumbo-sacral defect. There kyphoscoliosis over the area of the defect with total disruption of the normal spine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_13_24786=[""].join("\n");
var outline_f24_13_24786=null;
var title_f24_13_24787="Patient information: Echocardiogram (The Basics)";
var content_f24_13_24787=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16426\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/42/9888\">",
"         Normal heart",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"          Digestive system",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"           Person having an ECG",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/35/34354\">",
"            Transthoracic echocardiogram (echo)",
"           </a>",
"           <li>",
"            <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/21/32085\">",
"             Person having a stress test",
"            </a>",
"           </li>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?20/34/21027\">",
"         Patient information: Chest pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/10/27809\">",
"         Patient information: Coronary heart disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/13/21714\">",
"         Patient information: Dilated cardiomyopathy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/53/10068\">",
"         Patient information: Heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/42/36514\">",
"         Patient information: Heart murmurs (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/28/35266\">",
"         Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/60/19394\">",
"         Patient information: Mitral regurgitation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/31/12787\">",
"         Patient information: Mitral stenosis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/4/21571\">",
"         Patient information: Mitral valve prolapse (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?42/9/43157\">",
"         Patient information: Chest pain (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/17/44305\">",
"         Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/5/33877\">",
"         Patient information: Heart failure (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/49/18197\">",
"         Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Echocardiogram (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/echocardiogram-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H98935533\">",
"      <span class=\"h1\">",
"       What is an echocardiogram?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An echocardiogram, also called an &ldquo;echo,&rdquo; is an imaging test that creates pictures of your heart as it beats. During an echo, a doctor, nurse, or technician uses a thick wand, called a &ldquo;transducer&rdquo; or &ldquo;probe,&rdquo; to send sound waves into the heart. The sound waves create images that show the size of the heart chambers, how well the heart pumps, and how well the heart valves work (",
"      <a class=\"graphic graphic_figure graphicRef56936 \" href=\"UTD.htm?9/42/9888\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      An echo can be done in 2 main ways:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        The doctor, nurse, or technician can put the transducer on the outside of your chest &mdash; This is called a &ldquo;transthoracic echo,&rdquo; or &ldquo;TTE.&rdquo;",
"       </li>",
"       <li>",
"        The doctor can put a tube with the transducer on the end into your mouth and down into your esophagus (",
"        <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"         figure 2",
"        </a>",
"        ). This is called a &ldquo;transesophageal echo,&rdquo; or &ldquo;TEE.&rdquo;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sometimes, doctors do a test called a &ldquo;stress test&rdquo; along with a TTE. A stress test measures how well the heart works when it pumps very fast. When the heart pumps fast, it needs more blood. A stress test shows if the heart gets enough blood during these times. When a stress test is done with an echo, it&rsquo;s called a &ldquo;stress echo.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98935540\">",
"      <span class=\"h1\">",
"       Why might my doctor order an echo?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor might order an echo to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Look for a problem in the heart or in the blood vessels around the heart.",
"       </li>",
"       <li>",
"        Follow a known heart problem or condition.",
"       </li>",
"       <li>",
"        Help figure out the cause of symptoms such as shortness of breath, leg swelling, or an irregular heartbeat.",
"       </li>",
"       <li>",
"        Check your heart after a heart attack or heart surgery.",
"       </li>",
"       <li>",
"        Check how well your heart medicines are working.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor might order a stress echo to:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Check for heart problems that get worse or are visible only when the heart pumps fast.",
"       </li>",
"       <li>",
"        See if you can safely exercise after a heart attack.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98935547\">",
"      <span class=\"h1\">",
"       How do I prepare for an echo?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on how the echo is done.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        For a TTE, you don&rsquo;t need to do anything special to prepare.",
"       </li>",
"       <li>",
"        For a TEE, your doctor will ask you not to eat or drink for 8 hours beforehand.",
"       </li>",
"       <li>",
"        For a stress echo, your doctor will probably ask you not to eat, drink, or smoke for 3 hours beforehand. He or she might also change or stop some of your heart medicines, if you are on any.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98935554\">",
"      <span class=\"h1\">",
"       What happens during an echo?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Before the echo starts, the doctor, nurse, or technician will put some stickers on your chest to monitor your heartbeat (",
"      <a class=\"graphic graphic_figure graphicRef53145 \" href=\"UTD.htm?6/63/7154\">",
"       figure 3",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      For a TTE, you will lie on your back or left side. The doctor, nurse, or technician will put a small amount of gel on your chest. Then he or she will press the transducer against your chest and move it around. He or she might ask you to hold your breath or change positions during the test. Images of your heart will appear on a computer screen (",
"      <a class=\"graphic graphic_figure graphicRef77971 \" href=\"UTD.htm?33/35/34354\">",
"       figure 4",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      If you have a stress echo, the doctor, nurse, or technician will do an echo while you are resting. Then he or she will &ldquo;stress&rdquo; your heart and raise your heart rate with 1 of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have you run or walk on a treadmill (",
"        <a class=\"graphic graphic_figure graphicRef60855 \" href=\"UTD.htm?31/21/32085\">",
"         figure 5",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Have you pedal a stationary bike (a bike that doesn&rsquo;t move, except for the pedals)",
"       </li>",
"       <li>",
"        Give you medicine to make your heart pump faster &mdash; People who can&rsquo;t run or walk can get medicine instead of exercising.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Immediately after these, while your heart is still pumping fast, he or she will do another echo.",
"     </p>",
"     <p>",
"      For a TEE, you will have an IV (needle) put in your arm or hand. Your doctor will give you medicines through the IV to make you feel relaxed. He or she will give you a mouth spray or gargle to numb your throat. Then he or she will put a thin tube with a transducer on the end into your mouth and down into your esophagus. He or she will press the transducer against the esophagus wall to create images of the heart.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98935561\">",
"      <span class=\"h1\">",
"       What are the downsides of an echo?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on the type of echo.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A TTE does not have any downsides.",
"       </li>",
"       <li>",
"        A TEE can cause a sore throat or throat injury. The medicines used to help you relax can make you groggy. You will need someone to drive you home afterward.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      A stress echo can also have downsides. But they are caused by the stress test and not by the echo. When people exercise and their heart pumps very fast, they can have symptoms that include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        An abnormal heartbeat",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Feeling dizzy or faint",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98935660\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/60/19394?source=see_link\">",
"       Patient information: Mitral regurgitation (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=see_link\">",
"       Patient information: Heart attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/13/21714?source=see_link\">",
"       Patient information: Dilated cardiomyopathy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=see_link\">",
"       Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=see_link\">",
"       Patient information: Coronary heart disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/34/21027?source=see_link\">",
"       Patient information: Chest pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/42/36514?source=see_link\">",
"       Patient information: Heart murmurs (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/4/21571?source=see_link\">",
"       Patient information: Mitral valve prolapse (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/31/12787?source=see_link\">",
"       Patient information: Mitral stenosis in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/9/43157?source=see_link\">",
"       Patient information: Chest pain (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       Patient information: Heart failure (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/17/44305?source=see_link\">",
"       Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=see_link\">",
"       Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?24/13/24787?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16426 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-D8D1174216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_13_24787=[""].join("\n");
var outline_f24_13_24787=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98935533\">",
"      What is an echocardiogram?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98935540\">",
"      Why might my doctor order an echo?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98935547\">",
"      How do I prepare for an echo?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98935554\">",
"      What happens during an echo?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98935561\">",
"      What are the downsides of an echo?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98935660\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16426\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/42/9888\">",
"      Normal heart",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"       Digestive system",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"        Person having an ECG",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/35/34354\">",
"         Transthoracic echocardiogram (echo)",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/21/32085\">",
"          Person having a stress test",
"         </a>",
"        </li>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/9/43157?source=related_link\">",
"      Patient information: Chest pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/34/21027?source=related_link\">",
"      Patient information: Chest pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=related_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/17/44305?source=related_link\">",
"      Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/13/21714?source=related_link\">",
"      Patient information: Dilated cardiomyopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=related_link\">",
"      Patient information: Heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/42/36514?source=related_link\">",
"      Patient information: Heart murmurs (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/60/19394?source=related_link\">",
"      Patient information: Mitral regurgitation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/31/12787?source=related_link\">",
"      Patient information: Mitral stenosis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/4/21571?source=related_link\">",
"      Patient information: Mitral valve prolapse (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_13_24788="Miglustat: Drug information";
var content_f24_13_24788=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Miglustat: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/40/6788?source=see_link\">",
"    see \"Miglustat: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F196682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zavesca&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zavesca&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F196696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Enzyme Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F196684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Type 1 Gaucher disease:",
"     </b>",
"     Oral: 100 mg 3 times/day; dose may be reduced to 100 mg 1-2 times/day in patients with adverse effects (ie, tremor, GI distress)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Niemann-Pick Type C disease",
"     </b>",
"     <i>",
"      (Canadian labeling; not in U.S. labeling):",
"     </i>",
"     Oral: 200 mg 3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F12958851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     <b>",
"      Niemann-Pick Type C disease",
"     </b>",
"     <i>",
"      (Canadian labeling (not in U.S. labeling):",
"     </i>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &lt;12 years:",
"     <b>",
"      Note:",
"     </b>",
"     Children &lt;4 years of age were not included in clinical trials; dose based on body surface area (BSA):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     BSA &gt;1.25 m",
"     <sup>",
"      2",
"     </sup>",
"     : Miglustat 200 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     BSA &gt;0.88-1.25 m",
"     <sup>",
"      2",
"     </sup>",
"     : Miglustat 200 mg 2 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     BSA &gt;0.73-0.88 m",
"     <sup>",
"      2",
"     </sup>",
"     : Miglustat 100 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     BSA &gt;0.47-0.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Miglustat 100 mg 2 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     BSA &le;0.47 m",
"     <sup>",
"      2",
"     </sup>",
"     : Miglustat 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F196685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Gaucher disease:",
"     </i>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-70 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 100 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Niemann-Pick Type C disease:",
"     </i>",
"     Canadian labeling (not in U.S. labeling):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-70 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer two-thirds of regular dose in 2 equal doses  (adjusted for BSA)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer one-third of regular dose in 2 equal doses (adjusted for BSA)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-70 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 100 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Not recommended",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F196662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zavesca&reg;: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F196649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F196664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food. Capsules should be swallowed whole and taken at the same time each day at regular intervals. If patient is unable to tolerate or swallow capsule whole and  powder is administered, mix powder into a liquid immediately prior to use (do not store); sweetening agents are not expected to interact (data on file [Actelion Pharmaceuticals Ltd, 2011])",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F196663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of mild-to-moderate type 1 Gaucher disease when enzyme replacement therapy is not a therapeutic option",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional use (not in U.S. labeling): Treatment to delay the progression of neurological manifestations in Niemann-Pick Type C disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F10193844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Zavesca: Brand name for miglustat [U.S., Canada, and multiple international markets], but also brand name for escitalopram [in multiple international markets; ISMP April 21, 2010]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F196694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages reported from open-label, uncontrolled monotherapy trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (21% to 22%), dizziness (up to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (89% to 100%), weight loss (39% to 67%), abdominal pain (18% to 67%), flatulence (29% to 50%), nausea (8% to 22%), vomiting (4% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor (11% to 30%), weakness (17%), leg cramps (4% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Visual disturbances (up to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Memory impairment (8%), migraine (up to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Menstrual disorder (up to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distension (8%), constipation (8%), xerostomia (8%), bloating (up to 6%), anorexia (up to 7%), dyspepsia (up to 7%), epigastric pain (up to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (6% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (8%), gait instability (8%), paresthesia (up to 7%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F196667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to miglustat or any component of the formulation; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F196652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diarrhea: Observed in the majority of patients, many also reported weight loss. Incidence decreases over time; foods with high carbohydrate content should be avoided. If symptoms persist, patients should be evaluated for underlying GI disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathy: Has been reported; neurologic monitoring is required. Weigh risk versus benefit of therapy if patient develops numbness and tingling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Platelet counts decreased: Mild decrease in platelet counts (without bleeding) has been observed with use in Niemann-Pick Type C disease (not an approved use in the U.S.); monitor platelet counts in this patient population during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tremor: Exacerbations of existing tremor or tremor may occur; may resolve over time or respond to dosage reduction. Treatment discontinuation may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustments recommended. Not recommended in patients with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Severe type 1 Gaucher disease: Safety and efficacy have not been established in severe type 1 Gaucher disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Imiglucerase: Miglustat increases the clearance of imiglucerase; however, the clinical significance of this is not known; combination therapy is not indicated.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F196678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food decreases the rate, but not the extent, of absorption.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F196658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F196668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreased fetus weight, fetal loss, and difficult or delayed births were observed in animal studies. Women with reproduction potential should use effective contraception during therapy. In addition, adverse effects on spermatogenesis and reduced fertility were observed in male animal studies. The manufacturer recommends that male patients use reliable contraception during therapy and for 3 months following treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F196688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F196669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food. Patients with diarrhea should avoid foods with high carbohydrate content.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Zavesca Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (18): $4584.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F196660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neurologic evaluations baseline and repeated every 6 months; adverse effects; weight; vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     ; platelet counts and renal function in Niemann-Pick Type C patients (Canadian labeling recommendation); pregnancy test prior to therapy in women of reproductive age",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F196670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Zavesca (AT, AU, BE, BG, CH, CZ, DE, DK, EE, FI, FR, GB, GR, HN, IE, IL, IT, MT, NL, NO, NZ, PT, RU, SE, SK, TR, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F196651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Miglustat competitively and reversibly inhibits the enzyme needed to produce glycosphingolipids and decreases the rate of glycosphingolipid glucosylceramide formation. Glucosylceramide accumulates in type 1 Gaucher disease, causing complications specific to this disease.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F196666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 83-105 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: No binding to plasma proteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: No evidence of metabolism in humans",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 6-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 2-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10244 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-5A6B11C91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_13_24788=[""].join("\n");
var outline_f24_13_24788=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196682\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855146\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196696\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196684\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12958851\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062617\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196685\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196662\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196649\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196664\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196663\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10193844\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196694\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196667\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196652\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299712\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221699\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196678\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196658\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196668\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196688\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196669\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323414\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196660\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196670\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196651\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196666\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10244\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10244|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/40/6788?source=related_link\">",
"      Miglustat: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_13_24789="Hand and wrist PI";
var content_f24_13_24789=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F69018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F69018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Hand and wrist bones",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 610px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows the bones of the hand and wrist.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_13_24789=[""].join("\n");
var outline_f24_13_24789=null;
var title_f24_13_24790="Acute cholangitis";
var content_f24_13_24790=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute cholangitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/13/24790/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/13/24790/contributors\">",
"     Nezam H Afdhal, MD, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/13/24790/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/13/24790/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/13/24790/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/13/24790/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/13/24790/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/13/24790/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 21, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cholangitis is a clinical syndrome characterized by fever, jaundice, and abdominal pain that develops as a result of stasis and infection in the biliary tract. Cholangitis was first described by Charcot as a serious and life-threatening illness; however, it is now recognized that the severity can range from mild to life-threatening [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features and therapy of acute cholangitis will be reviewed here. The management of common bile duct stones and AIDS cholangiopathy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=see_link\">",
"     \"Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26069?source=see_link\">",
"     \"AIDS cholangiopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cholangitis is caused primarily by bacterial infection. The organisms typically ascend from the duodenum; hematogenous spread from the portal vein is a rare source of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most important predisposing factor for acute cholangitis is biliary obstruction and stasis secondary to biliary calculi or benign stricture (",
"    <a class=\"graphic graphic_picture graphicRef65633 \" href=\"UTD.htm?34/17/35093\">",
"     picture 1",
"    </a>",
"    ). Chronic biliary obstruction raises the intrabiliary pressure, a central pathogenetic event in the development of acute cholangitis. High pressure promotes the migration of bacteria from the portal circulation into the biliary tract and subsequent colonization. It also favors migration of bacteria from bile into the systemic circulation, resulting in a higher incidence of septicemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/2\">",
"     2",
"    </a>",
"    ]. One study, for example, demonstrated a significant correlation between biliary and serum levels of endotoxins and the clinical severity of acute cholangitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, increased biliary pressure adversely affects a number of host defense mechanisms including [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hepatic tight junctions",
"     </li>",
"     <li>",
"      Kupffer cells",
"     </li>",
"     <li>",
"      Bile flow",
"     </li>",
"     <li>",
"      IgA production",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanism of bacterial entry into the biliary tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sphincter of Oddi normally forms an effective mechanical barrier to duodenal reflux and ascending bacterial infection. The continuous flushing action of bile plus the bacteriostatic activity of bile salts also help to maintain bile sterility. Secretory IgA and biliary mucous probably function as antiadherent factors, preventing bacterial colonization.",
"   </p>",
"   <p>",
"    When the barrier mechanism is disrupted, as occurs after endoscopic sphincterotomy, choledochal surgery, or biliary stent insertion, pathogenic bacteria enter the biliary system at high concentrations. Thus, cholangitis frequently develops after endoscopic or percutaneous manipulation with incomplete biliary drainage or as a late complication of stent blockage.",
"   </p>",
"   <p>",
"    However, bacteria can also pass spontaneously through the sphincter of Oddi in small numbers. The presence of a foreign body, such as a stone or stent, can then act as a nidus for bacterial colonization. Bile taken from patients without obstruction is sterile or nearly sterile [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/4\">",
"     4",
"    </a>",
"    ]. In comparison, approximately 70 percent of all patients with gallstones have evidence of bacteria in the bile [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Patients with common duct stones have a higher probability of bile culture positivity than those with gallstones in the gallbladder or cystic duct [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bacteria can also be cultured from gallstones. In one study, for example, 80 percent of brown pigment stones were culture positive, and 84 percent showed scanning electron microscopic evidence of bacterial structures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/6\">",
"     6",
"    </a>",
"    ]. The organisms recovered in culture were typical of those seen in cholangitis (enterococci &mdash; 40 percent; Escherichia coli &mdash; 17 percent; Klebsiella spp &mdash; 10 percent), although the ratio of enterococci and E. coli was inverted from that usually found in infected bile.",
"   </p>",
"   <p>",
"    Some features of bacteria that may enhance pathogenicity in this setting include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      External pili in Gram negative Enterobacteriaceae, which facilitate attachment to foreign surfaces such as a stone or stent.",
"     </li>",
"     <li>",
"      A glycocalyx matrix composed of exopolysaccharides produced by bacteria which protect the organisms from host defense mechanisms and may hinder penetration of antibiotics [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bacteriology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Culture of bile, ductal stones, and blocked biliary stents are positive in over 90 percent of cases, yielding a mixed growth of gram negative and gram positive bacteria. The most common bacteria isolated are of colonic origin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Escherichia coli is the major gram negative bacterium isolated (25 to 50 percent), followed by Klebsiella (15 to 20 percent) and Enterobacter species (5 to 10 percent).",
"     </li>",
"     <li>",
"      The most common gram positive bacteria are Enterococcus species (10 to 20 percent).",
"     </li>",
"     <li>",
"      Anaerobes, such as Bacteroides and Clostridia, are usually present as a mixed infection. They are rarely the sole infecting organisms and it is not clear if they play a role in acute cholangitis. Recovery of anaerobes appears to be more common after repeated infections or surgery on the biliary tree. The frequency of anaerobic infection is underestimated by standard culture techniques.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic triad of Charcot &mdash; fever, right upper quadrant pain, and jaundice &mdash; occurs in only 50 to 75 percent of patients with acute cholangitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/8\">",
"     8",
"    </a>",
"    ]. Confusion and hypotension can occur in patients with suppurative cholangitis, producing Reynold's pentad, which is associated with significant morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/9\">",
"     9",
"    </a>",
"    ]. Hypotension may be the only presenting symptom in elderly patients or those on corticosteroids, while septic shock in severe cases can lead to multiorgan failure.",
"   </p>",
"   <p>",
"    The differential diagnosis includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Biliary leaks",
"     </li>",
"     <li>",
"      Liver abscess",
"     </li>",
"     <li>",
"      Infected choledochal cysts",
"     </li>",
"     <li>",
"      Recurrent pyogenic cholangitis",
"     </li>",
"     <li>",
"      Cholecystitis",
"     </li>",
"     <li>",
"      Mirizzi syndrome",
"     </li>",
"     <li>",
"      Right lower lobe",
"      <span class=\"nowrap\">",
"       pneumonia/empyema",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory tests typically reveal an elevated white blood cell count with neutrophil predominance, and a cholestatic pattern of liver test abnormalities, with elevations in the serum alkaline phosphatase, gammaglutamyl transpeptidase (GGT), and bilirubin (predominantly conjugated) concentration. Serum amylase can be increased to three to four times normal, suggesting an associated pancreatitis.",
"   </p>",
"   <p>",
"    However, a pattern of acute hepatocyte necrosis can be seen in which the aminotransferases may be as high as 1000",
"    <span class=\"nowrap\">",
"     IU/L.",
"    </span>",
"    This pattern reflects microabscess formation in the liver. Liver biopsy in such cases shows neutrophils in the cholangioles with small abscesses and associated hepatocyte necrosis.",
"   </p>",
"   <p>",
"    Blood cultures should be performed in all patients in whom cholangitis is suspected. Cultures should also be obtained from bile or stents removed at ERCP (endoscopic retrograde cholangiopancreatography). Antibiotic therapy should be directed at any organisms isolated from these cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend ultrasonography as the first imaging study in patients suspected of having cholangitis to look for CBD dilatation and stones. However, ultrasonography may be negative when only small stones are present in the bile ducts (which occurs in 10 to 20 percent of cases), and with acute obstruction when the bile duct has not yet had time to dilate (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62967 \" href=\"UTD.htm?26/11/26815\">",
"     image 1",
"    </a>",
"    ). Ultrasonography should be followed by endoscopic retrograde cholangiopancreatography (ERCP) both to confirm the diagnosis and to intervene therapeutically with sphincterotomy, stone extraction, or stent insertion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70088 \" href=\"UTD.htm?10/34/10798\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef67640 \" href=\"UTD.htm?31/32/32258\">",
"     picture 2",
"    </a>",
"    ). Occlusive cholangiography should not be performed in patients with acute suppurative cholangitis since it can promote the development of septicemia (",
"    <a class=\"graphic graphic_picture graphicRef69133 \" href=\"UTD.htm?14/10/14510\">",
"     picture 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=see_link\">",
"     \"Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Magnetic resonance cholangiopancreatography (MRCP) is a newer technique for the evaluation of CBD stones, particularly in the patient who is postcholecystectomy or in whom ERCP was unsuccessful or failed to completely delineate ductal abnormalities (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57884 \" href=\"UTD.htm?35/9/35986\">",
"     image 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. In the presence of a dilated CBD, this test has a 90 to 95 percent concordance with ERCP in diagnosing CBD stones over 1 cm in diameter (",
"    <a class=\"graphic graphic_picture graphicRef77802 \" href=\"UTD.htm?3/9/3217\">",
"     picture 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. If cholangitis is not severe and the risks of ERCP are high, then MRCP may be useful, especially if no stones are demonstrated. If, however, Charcot's triad is present, a therapeutic ERCP with drainage of the obstruction should not be delayed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=see_link\">",
"     \"Magnetic resonance cholangiopancreatography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endoscopic ultrasound provides another means to visualize common duct stones. While its role remains unclear, it may be useful in patients in whom ERCP was unsuccessful or undesirable (such as pregnant women) and those at increased risk for ERCP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43557?source=see_link\">",
"     \"Endoscopic ultrasound in patients with suspected choledocholithiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstays of therapy are antibiotics and establishment of biliary drainage. Other general measures include fluids to maintain urine output, correction of coagulopathy, and frequent monitoring of vital signs for evidence of sepsis. In cases of suspected sepsis, monitoring for multiorgan failure from endotoxemia is essential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are little data and no consensus opinions regarding the best initial antibiotic regimen for cholangitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/7,13-16\">",
"     7,13-16",
"    </a>",
"    ]. Beta lactam-based therapy appears to be as effective as treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    with less toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/16\">",
"     16",
"    </a>",
"    ]. Fluoroquinolones appear to have relatively high rates of biliary excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/13\">",
"     13",
"    </a>",
"    ], and one study found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    may be as effective as triple therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    , ampicillin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Empiric antibiotic therapy for ascending cholangitis should include broad-spectrum parenteral antibiotics based upon the probable source of infection until culture results are available (",
"    <a class=\"graphic graphic_table graphicRef67894 \" href=\"UTD.htm?7/21/7517\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Bacteriology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Regardless of initial drug regimen, therapy should be modified to reflect the organism(s) recovered in blood cultures, if any. In general, antibiotics should be continued for seven to ten days, although the duration should be tailored to clinical improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Biliary drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eighty percent of patients with acute cholangitis will respond to conservative management and antibiotic therapy. Biliary drainage can then be performed on an elective basis. In 15 to 20 percent of cases, cholangitis fails to settle over the first 24 hours with conservative therapy alone, requiring urgent biliary decompression. Independent risk factors for developing acute suppurative cholangitis (a severe form of cholangitis) in patients with common bile duct stones include impacted stones, active smoker status, age &gt;70 years, and additional stones within the gallbladder [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indications for urgent biliary decompression include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistent abdominal pain",
"     </li>",
"     <li>",
"      Hypotension despite adequate resuscitation",
"     </li>",
"     <li>",
"      Fever greater than 39&ordm;C (102&ordm;F)",
"     </li>",
"     <li>",
"      Mental confusion, which is a predictor of poor outcome",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Establishment of biliary drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliary drainage can be achieved by ERCP, a direct percutaneous approach, or open surgical decompression. Endoscopic sphincterotomy with stone extraction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stent insertion is now the treatment of choice for establishing biliary drainage in acute cholangitis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62967 \" href=\"UTD.htm?26/11/26815\">",
"     image 1",
"    </a>",
"    ). Common bile duct stones can be removed successfully in 90 to 95 percent of patients after sphincterotomy. Prior to injection of contrast, many endoscopists aspirate the bile duct to remove bile and pus in an attempt to decompress the biliary system and reduce the risk of inducing bacteremia with contrast injection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=see_link\">",
"     \"Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endoscopic drainage is associated with significantly lower overall rates of mortality and morbidity compared with surgical decompression (mortality rates of 4.7 to 10 percent versus 10 to 50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. As mentioned above, occlusive cholangiography should not be performed in patients with acute suppurative cholangitis since it can promote the development of septicemia (",
"    <a class=\"graphic graphic_picture graphicRef69133 \" href=\"UTD.htm?14/10/14510\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In patients with underlying coagulopathies that prevent sphincterotomy, in those in whom drainage is inadequate due to the presence of large stones, or in those who are too ill to leave the intensive care unit and undergo the procedure with fluoroscopy, drainage can be achieved by insertion of a nasobiliary catheter. This procedure permits active decompression of the CBD by aspiration and provides a route for irrigation of the biliary system [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. However, the catheters can become dislodged, particularly in elderly or confused patients.",
"   </p>",
"   <p>",
"    An internal stent may be another option with a lower risk of dislodgement, although it does not permit injection of contrast or irrigation. A controlled trial suggested that an internal stent permitted adequate drainage even when performed without a sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stones more than 2 cm in diameter generally require lithotripsy for fragmentation prior to removal. Intrahepatic stones can sometimes be removed with choledochoscopy, depending upon their size, number, and location. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=see_link\">",
"     \"Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21897?source=see_link\">",
"     \"Cholangioscopy and pancreatoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Percutaneous drainage can be considered when ERCP is unavailable, unsuccessful or contraindicated. A percutaneous cholecystostomy tube may be an option in patients with an intact gallbladder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Role of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergency surgery for acute cholangitis has largely been replaced by nonoperative biliary drainage. Once the acute cholangitis is controlled, patients with difficult ductal stones may undergo surgical exploration of the CBD for stone removal. Elective surgery carries a very low morbidity and mortality compared with emergency surgery. If emergent surgery is needed due to failure of a nonsurgical drainage procedure, choledochotomy with placement of a large-bore T tube carries a lower mortality compared to cholecystectomy with CBD exploration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24790/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6440?source=see_link\">",
"     \"Common bile duct exploration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;With effective antibiotics and biliary drainage, the prognosis for mild to moderate cholangitis is much improved. However, the mortality rate remains very high (approximately 50 percent) for patients with severe cholangitis (Reynold's pentad).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute cholangitis is a clinical syndrome characterized by fever, jaundice, and abdominal pain that develops as a result of stasis and infection in the biliary tract. The classic triad of Charcot &mdash; fever, right upper quadrant pain, and jaundice &mdash; occurs in only 50 to 75 percent of patients. Confusion and hypotension can occur in patients with suppurative cholangitis, producing Reynold's pentad, which is associated with significant morbidity and mortality. Hypotension may be the only presenting symptom in elderly patients or those taking corticosteroids, while septic shock in severe cases can lead to multiorgan failure. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis includes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Biliary leaks",
"     </li>",
"     <li>",
"      Liver abscess",
"     </li>",
"     <li>",
"      Infected choledochal cysts",
"     </li>",
"     <li>",
"      Oriental cholangiohepatitis",
"     </li>",
"     <li>",
"      Cholecystitis",
"     </li>",
"     <li>",
"      Mirizzi syndrome",
"     </li>",
"     <li>",
"      Right lower lobe",
"      <span class=\"nowrap\">",
"       pneumonia/empyema",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mainstays of therapy are antibiotics and establishment of biliary drainage. Other general measures include fluids to maintain urine output, correction of coagulopathy, and frequent monitoring of vital signs for evidence of sepsis. In cases of suspected sepsis, monitoring for multiorgan failure from endotoxemia is essential.",
"     </li>",
"     <li>",
"      Antibiotic choices are summarized above. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Eighty percent of patients with acute cholangitis will respond to conservative management and antibiotic therapy. Biliary drainage can then be performed on an elective basis. In 15 to 20 percent of cases, cholangitis fails to settle over the first 24 hours with conservative therapy alone, requiring urgent biliary decompression. Indications for urgent biliary decompression include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Persistent abdominal pain",
"     </li>",
"     <li>",
"      Hypotension despite adequate resuscitation",
"     </li>",
"     <li>",
"      Fever greater than 39&ordm;C (102&ordm;F)",
"     </li>",
"     <li>",
"      Mental confusion, which is a predictor of poor outcome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biliary drainage can be achieved by ERCP, a direct percutaneous approach, or open surgical decompression. We recommend endoscopic sphincterotomy with stone extraction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      stent insertion for establishing biliary drainage in acute cholangitis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62967 \" href=\"UTD.htm?26/11/26815\">",
"       image 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Common bile duct stones can be removed successfully in 90 to 95 percent of patients after sphincterotomy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=see_link\">",
"       \"Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      With effective antibiotics and biliary drainage, the prognosis for mild to moderate cholangitis is much improved. However, the mortality rate remains very high (approximately 50 percent) for patients with severe cholangitis (Reynold's pentad).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/1\">",
"      Boey JH, Way LW. Acute cholangitis. Ann Surg 1980; 191:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/2\">",
"      Sung JY, Costerton JW, Shaffer EA. Defense system in the biliary tract against bacterial infection. Dig Dis Sci 1992; 37:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/3\">",
"      Lau JY, Chung SC, Leung JW, et al. Endoscopic drainage aborts endotoxaemia in acute cholangitis. Br J Surg 1996; 83:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/4\">",
"      Csendes A, Becerra M, Burdiles P, et al. Bacteriological studies of bile from the gallbladder in patients with carcinoma of the gallbladder, cholelithiasis, common bile duct stones and no gallstones disease. Eur J Surg 1994; 160:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/5\">",
"      Ohdan H, Oshiro H, Yamamoto Y, et al. Bacteriological investigation of bile in patients with cholelithiasis. Surg Today 1993; 23:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/6\">",
"      Leung JW, Sung JY, Costerton JW. Bacteriological and electron microscopy examination of brown pigment stones. J Clin Microbiol 1989; 27:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/7\">",
"      van den Hazel SJ, Speelman P, Tytgat GN, et al. Role of antibiotics in the treatment and prevention of acute and recurrent cholangitis. Clin Infect Dis 1994; 19:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/8\">",
"      Saik RP, Greenburg AG, Farris JM, Peskin GW. Spectrum of cholangitis. Am J Surg 1975; 130:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/9\">",
"      DenBesten L, Doty JE. Pathogenesis and management of choledocholithiasis. Surg Clin North Am 1981; 61:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/10\">",
"      Chan YL, Chan AC, Lam WW, et al. Choledocholithiasis: comparison of MR cholangiography and endoscopic retrograde cholangiography. Radiology 1996; 200:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/11\">",
"      Lee MG, Lee HJ, Kim MH, et al. Extrahepatic biliary diseases: 3D MR cholangiopancreatography compared with endoscopic retrograde cholangiopancreatography. Radiology 1997; 202:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/12\">",
"      Soto JA, Yucel EK, Barish MA, et al. MR cholangiopancreatography after unsuccessful or incomplete ERCP. Radiology 1996; 199:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/13\">",
"      Leung JW, Ling TK, Chan RC, et al. Antibiotics, biliary sepsis, and bile duct stones. Gastrointest Endosc 1994; 40:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/14\">",
"      Sinanan MN. Acute cholangitis. Infect Dis Clin North Am 1992; 6:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/15\">",
"      Sung JJ, Lyon DJ, Suen R, et al. Intravenous ciprofloxacin as treatment for patients with acute suppurative cholangitis: a randomized, controlled clinical trial. J Antimicrob Chemother 1995; 35:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/16\">",
"      Gerecht WB, Henry NK, Hoffman WW, et al. Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and gentamicin therapy for patients with cholangitis. Arch Intern Med 1989; 149:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/17\">",
"      Yeom DH, Oh HJ, Son YW, Kim TH. What are the risk factors for acute suppurative cholangitis caused by common bile duct stones? Gut Liver 2010; 4:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/18\">",
"      Lai EC, Mok FP, Tan ES, et al. Endoscopic biliary drainage for severe acute cholangitis. N Engl J Med 1992; 326:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/19\">",
"      Chijiiwa K, Kozaki N, Naito T, et al. Treatment of choice for choledocholithiasis in patients with acute obstructive suppurative cholangitis and liver cirrhosis. Am J Surg 1995; 170:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/20\">",
"      Leese T, Neoptolemos JP, Baker AR, Carr-Locke DL. Management of acute cholangitis and the impact of endoscopic sphincterotomy. Br J Surg 1986; 73:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/21\">",
"      Lai EC, Tam PC, Paterson IA, et al. Emergency surgery for severe acute cholangitis. The high-risk patients. Ann Surg 1990; 211:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/22\">",
"      Leung JW, Cotton PB. Endoscopic nasobiliary catheter drainage in biliary and pancreatic disease. Am J Gastroenterol 1991; 86:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/23\">",
"      Lee DW, Chan AC, Lam YH, et al. Biliary decompression by nasobiliary catheter or biliary stent in acute suppurative cholangitis: a prospective randomized trial. Gastrointest Endosc 2002; 56:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24790/abstract/24\">",
"      Hui CK, Lai KC, Yuen MF, et al. Does the addition of endoscopic sphincterotomy to stent insertion improve drainage of the bile duct in acute suppurative cholangitis? Gastrointest Endosc 2003; 58:500.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 658 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-5917900B73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_13_24790=[""].join("\n");
var outline_f24_13_24790=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanism of bacterial entry into the biliary tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bacteriology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Biliary drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Establishment of biliary drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Role of surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/658\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/658|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/11/26815\" title=\"diagnostic image 1\">",
"      Acute cholangitis ERCP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/34/10798\" title=\"diagnostic image 2\">",
"      Obstructing CBD stone ERCP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/9/35986\" title=\"diagnostic image 3\">",
"      Acute cholangitis MRCP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/658|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/17/35093\" title=\"picture 1\">",
"      CBD stone acute cholangitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/32/32258\" title=\"picture 2\">",
"      Endosc stone extraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/10/14510\" title=\"picture 3\">",
"      Suppurative cholangitis Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/9/3217\" title=\"picture 4\">",
"      Acute cholangitis ERCP 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/658|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/21/7517\" title=\"table 1\">",
"      Empiric therapy gram negatives and anaerobes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26069?source=related_link\">",
"      AIDS cholangiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21897?source=related_link\">",
"      Cholangioscopy and pancreatoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6440?source=related_link\">",
"      Common bile duct exploration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=related_link\">",
"      Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43557?source=related_link\">",
"      Endoscopic ultrasound in patients with suspected choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=related_link\">",
"      Magnetic resonance cholangiopancreatography",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_13_24791="Rasagiline: Drug information";
var content_f24_13_24791=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rasagiline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/45/18133?source=see_link\">",
"    see \"Rasagiline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2985038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Azilect&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14476718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Azilect&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2985062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-Parkinson's Agent, MAO Type B Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2985104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Parkinson's disease:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Monotherapy: 1 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adjunctive therapy with levodopa: Initial: 0.5 mg once daily; may increase to 1 mg once daily based on response and tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     When added to existing levodopa therapy, a dose reduction of levodopa may be required to avoid exacerbation of dyskinesias; typical dose reductions of ~9% to 13% were employed in clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dose reduction with concomitant ciprofloxacin or other CYP1A2 inhibitors:",
"     </b>",
"     0.5 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2985105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Mild-to-moderate impairment: No adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Severe impairment: Not studied.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F2985106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild impairment (Child-Pugh &le;6): 0.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Moderate-to-severe impairment: Not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2985118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Azilect&reg;: 0.5 mg, 1 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2985040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9780626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer without regard to meals.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2985065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of idiopathic Parkinson&rsquo;s disease (initial monotherapy or as adjunct to levodopa)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3370799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Azilect&reg; may be confused with Aricept&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2985076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Unless otherwise noted, the following adverse reactions are as reported for monotherapy. Spectrum of adverse events was generally similar with adjunctive (levodopa) therapy, though the incidence tended to be higher.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension (6% to 13% adjunct therapy, dose dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dyskinesia (18% adjunct therapy), headache (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (10% to 12% adjunct therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Angina, bundle branch block, chest pain, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression (5%), hallucinations (4% to 5% adjunct therapy), fever (3%), malaise (2%), vertigo (2%), anxiety, dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Bruising (2%), alopecia, skin carcinoma, vesiculobullous rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Impotence, libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (4% to 9% adjunct therapy), weight loss (2% to 9% adjunct therapy; dose dependent), dyspepsia (7%), xerostomia (2% to 6% adjunct therapy; dose dependent), gastroenteritis (3%), anorexia, diarrhea, gastrointestinal hemorrhage, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Hematuria, urinary incontinence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver function tests increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (7%), neck pain (2%), arthritis (2%), paresthesia (2%), abnormal gait, hyperkinesias, hypertonia, neuropathy, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Albuminuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (3%), asthma, cough increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Fall (5%), flu-like syndrome (5%), allergic reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%, postmarketing, and/or case reports (limited to important or life-threatening): Acute kidney failure, aphasia, apnea, atrial arrhythmia, AV block, bigeminy, blepharitis, blindness, bone necrosis, cerebral hemorrhage, cerebral ischemia, circumoral paresthesia, deafness, deep thrombophlebitis, delirium, diplopia, dysautonomia, dysesthesia, emphysema, esophageal ulcer, exfoliative dermatitis, facial paralysis, glaucoma, gynecomastia, heart failure, hematemesis, hemiplegia, hemorrhage (various locations), hostility, hypersexuality, hypertension, hypocalcemia, impulse control symptoms, interstitial pneumonia, intestinal obstruction, intestinal perforation, intestinal stenosis, jaundice, keratitis, kidney calculus, large intestine perforation, laryngismus, larynx edema, leukoderma, leukorrhea, libido increased, lung fibrosis, macrocytic anemia, manic depressive reaction, mania, megacolon, menstrual abnormalities, MI, muscle atrophy, myelitis, neuralgia, neuritis, neurosis, nocturia, paranoid reaction, parosmia, pathological gambling, personality disorder, pleural effusion, pneumothorax, polyuria, psychosis, psychotic depression, ptosis, purpura, retinal degeneration, retinal detachment, seizure, stomach ulcer, strabismus, stupor, thrombocythemia, thrombosis, tongue edema, urinary disorders, vaginal moniliasis, ventricular fibrillation, ventricular tachycardia, vestibular disorder, visual field defect",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2985071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Concomitant use of cyclobenzaprine, dextromethorphan, methadone, propoxyphene, St John&rsquo;s wort, or tramadol; concomitant use of meperidine or an MAO inhibitor (including selective MAO-B inhibitors) within 14 days of rasagiline",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2985072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause hallucinations; signs of severe CNS toxicity (some fatal), including hyperpyrexia, hyperthermia, rigidity, altered mental status, seizure and coma have been reported in combination with antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Melanoma: Risk of melanoma may be increased with rasagiline, although increased risk has been associated with Parkinson&rsquo;s disease itself; patients should have regular and frequent skin examinations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension, particularly in combination with levodopa; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia). Orthostatic hypotension occurs most frequently during the first 2 months of therapy and decreases over time.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome (SS)/neuroleptic malignant syndrome (NMS)-like reactions: SS and NMS-like reactions may occur rarely, particularly when used at doses exceeding recommendations or when used in combination with an antidepressant (eg, SSRI, SNRI, TCA). The diagnosis of SS can be made using the Hunter Serotonin Toxicity Criteria (Dunkley, 2003). Identification and differentiation of SS (eg, tremor, myoclonus, agitation) and more severe NMS-like reactions (eg, hyperthermia, muscle rigidity, autonomic instability, mental status changes) can be complex; monitor patients closely for either syndrome. Discontinue treatment (and any concomitant antidepressants) immediately if signs/symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild hepatic impairment; dose reduction recommended. Avoid with moderate-to-severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antidepressants: Use of rasagiline with tricyclic antidepressants, SNRIs, and SSRIs has been associated with rare reactions including serotonin syndrome and should generally be avoided. Do not use within 5 weeks of fluoxetine discontinuation; do not initiate tricyclic, SSRI, or SNRI therapy within 2 weeks of discontinuing rasagiline.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ciprofloxacin and other CYP1A2 inhibitors: Use with caution when used in combination with ciprofloxacin and other CYP1A2 inhibitors; may increase rasagiline concentrations; dose reduction recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Levodopa: Addition of rasagiline to levodopa therapy may result in exacerbation of levodopa adverse effects (eg, dyskinesia), requiring a reduction in levodopa dosage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tyramine-containing products: In patients taking recommended doses of rasagiline, dietary restriction of most tyramine-containing products is not necessary; however, certain foods (eg, aged cheeses) may contain high amounts (&gt;150 mg) of tyramine and could lead to hypertensive crisis. Avoid concomitant use with foods high in tyramine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F2985083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     Monoamine Oxidase",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2985082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): MAO Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Indirect-Acting): MAO Inhibitors may enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: MAO Inhibitors may enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists (Ophthalmic): MAO Inhibitors may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of MAO Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: MAO Inhibitors may enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome. Management: Avoid use of fentanyl (and other anilidopiperidine opioids when possible) in patients who have used a monoamine oxidase inhibitor within the past 14 days due to reports of unpredictable but severe adverse effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): MAO Inhibitors may enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: MAO Inhibitors may enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: MAO Inhibitors may enhance the neurotoxic (central) effect of AtoMOXetine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: MAO Inhibitors may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: MAO Inhibitors may enhance the neurotoxic (central) effect of BuPROPion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the adverse/toxic effect of MAO Inhibitors. Specifically, blood pressure elevations been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May enhance the adverse/toxic effect of MAO Inhibitors. Management: Avoid concurrent use of carbamazepine during, or within 14 days of discontinuing, treatment with a monoamine oxidase inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclobenzaprine: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: MAO Inhibitors may enhance the hypertensive effect of Dexmethylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: MAO Inhibitors may enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diethylpropion: MAO Inhibitors may enhance the hypertensive effect of Diethylpropion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxapram: MAO Inhibitors may enhance the hypertensive effect of Doxapram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HYDROmorphone: MAO Inhibitors may enhance the adverse/toxic effect of HYDROmorphone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: MAO Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: May enhance the adverse/toxic effect of MAO Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: MAO Inhibitors may enhance the adverse/toxic effect of Linezolid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: MAO Inhibitors may enhance the adverse/toxic effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maprotiline: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: MAO Inhibitors may enhance the serotonergic effect of Meperidine. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: MAO Inhibitors may enhance the adverse/toxic effect of Methadone.  Management: Initial safety testing, where small incremental doses of methadone are given with the patient closely monitored (including vitals, etc.), is recommended if methadone is to be used with (or within 14 days of) an MAO inhibitor. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa: MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: MAO Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: MAO Inhibitors may enhance the hypertensive effect of Methylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: MAO Inhibitors may enhance the neurotoxic (central) effect of Mirtazapine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orthostatic Hypotension Producing Agents: MAO Inhibitors may enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oxymorphone: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pizotifen: MAO Inhibitors may enhance the anticholinergic effect of Pizotifen.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: MAO Inhibitors may enhance the adverse/toxic effect of Reserpine. Existing MAOI therapy can result in paradoxical effects of added reserpine (e.g., excitation, hypertension).  Management: Monoamine oxidase inhibitors (MAOIs) should be avoided or used with great caution in patients who are also receiving reserpine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: MAO Inhibitors may decrease the metabolism of Serotonin 5-HT1D Receptor Agonists.  Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Eletriptan; Frovatriptan; Naratriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tapentadol: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrahydrozoline (Nasal): MAO Inhibitors may enhance the hypertensive effect of Tetrahydrozoline (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors. Management: Consider alternatives to combined treatment with tramadol and monoamine oxidase inhibitors due to an increased risk of serotonin syndrome and seizures. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: MAO Inhibitors may enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2985086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Concurrent ingestion of foods rich in tyramine may cause sudden and severe high blood pressure (hypertensive crisis). Management: Avoid foods containing high amounts (&gt;150 mg) of tyramine (aged or matured cheese, air-dried or cured meats including sausages and salamis; fava or broad bean pods, tap/draft beers, Marmite concentrate, sauerkraut, soy sauce, and other soybean condiments). Food&rsquo;s freshness is also an important concern; improperly stored or spoiled food can create an environment in which tyramine concentrations may increase. Avoid these foods during and for 2 weeks after discontinuation of medication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Some herbal medications may cause excessive sedation; others may increase the risk of serotonin syndrome or hypertensive reactions. Management: Avoid valerian, St John's wort, SAMe, and kava kava; avoid supplements containing caffeine, tyrosine, tryptophan, or phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2985066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2985067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Animal studies have documented decreased offspring survival and birth weight. An increased incidence of teratogenic effects, embryo-fetal deaths, and cardiovascular abnormalities were also noted with rasagiline in combination with levodopa/carbidopa. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2985069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2985070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Animal studies have shown rasagiline is capable of inhibiting prolactin secretion.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F2985107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals. Avoid products containing high amounts of tyramine (&gt;150 mg), such as aged cheeses (eg, Stilton cheese). Restriction of tyramine-containing products with lower amounts (&lt;150 mg) of tyramine is not necessary in patients taking recommended doses. Some examples of tyramine-containing products include aged or matured cheese, air-dried or cured meats (including sausages and salamis), fava or broad bean pods, tap/draft beers, Marmite concentrate, sauerkraut, soy sauce and other soybean condiments. Food&rsquo;s freshness is also an important concern; improperly stored or spoiled food can create an environment where tyramine concentrations may increase.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Azilect Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (30): $492.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (30): $492.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2985110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Blood pressure; symptoms of parkinsonism; general mood and behavior (increased anxiety, or presence of mania or agitation); skin examination for presence of melanoma (higher incidence in Parkinson&rsquo;s patients- drug causation not established)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Azilect (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IL, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Elbrus (AR);",
"     </li>",
"     <li>",
"      Menuix (CN);",
"     </li>",
"     <li>",
"      Rasalect (IN);",
"     </li>",
"     <li>",
"      Rasax (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2985089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Potent, irreversible and selective inhibitor of brain monoamine oxidase (MAO) type B, which plays a major role in the catabolism of dopamine. Inhibition of dopamine depletion in the striatal region of the brain reduces the symptomatic motor deficits of Parkinson&rsquo;s disease. There is also experimental evidence of rasagiline conferring neuroprotective effects (antioxidant, antiapoptotic), which may delay onset of symptoms and progression of neuronal deterioration.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2985090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Onset of action: Therapeutic: Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: ~1 week (irreversible inhibition); may require ~14-40 days for complete restoration of (brain) MAO-B activity",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Protein binding: 88% to 94%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic N-dealkylation and/or hydroxylation via CYP1A2 to multiple inactive metabolites (nonamphetamine derivatives)",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 87 L",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Bioavailability: ~36%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~1.3-3 hours (no correlation with biologic effect due to irreversible inhibition)",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Time to peak, plasma: ~1 hour",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Excretion: Urine (62%, &lt;1% of total dose as unchanged drug); feces (7%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chen JJ and Ly A-V, &ldquo;Rasagiline: A Second-Generation Monoamine Oxidase Type-B Inhibitor for the Treatment of Parkinson&rsquo;s Disease,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2006, 63(10):915-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/13/24791/abstract-text/16675649/pubmed\" id=\"16675649\" target=\"_blank\">",
"        16675649",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chen JJ and Swope DM, &ldquo;Clinical Pharmacology of Rasagiline: A Novel, Second-Generation Propargylamine for the Treatment of Parkinson Disease,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2005, 45(8):878-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/13/24791/abstract-text/16027398/pubmed\" id=\"16027398\" target=\"_blank\">",
"        16027398",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dunkley EJ, Isbister GK, Sibbritt D, et al, &ldquo;The Hunter Serotonin Toxicity Criteria: Simple and Accurate Diagnostic Decision Rules for Serotonin Toxicity,&rdquo;",
"      <i>",
"       QJM",
"      </i>",
"      , 2003, 96(9):635-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/13/24791/abstract-text/12925718/pubmed\" id=\"12925718\" target=\"_blank\">",
"        12925718",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hubalek F, Binda C, Li M et al, &ldquo;Inactivation of Purified Human Recombinant Monoamine Oxidases A and B by Rasagiline and its Analogues,&rdquo;",
"      <i>",
"       J Med Chem",
"      </i>",
"      , 2004, 47(7):1760-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/13/24791/abstract-text/15027867/pubmed\" id=\"15027867\" target=\"_blank\">",
"        15027867",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Huyse FJ, Touw DJ, van Schijndel RS, et al, &ldquo;Psychotropic Drugs and the Perioperative Period: A Proposal for a Guideline in Elective Surgery,&rdquo;",
"      <i>",
"       Psychosomatics",
"      </i>",
"      , 2006, 47(1):8-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/13/24791/abstract-text/16384803/pubmed\" id=\"16384803\" target=\"_blank\">",
"        16384803",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parkinson Study Group, &ldquo;A Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease,&rdquo;",
"      <i>",
"       Arch Neurol",
"      </i>",
"      , 2004, 6(4):561-66.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parkinson Study Group, &ldquo;A Controlled Trial of Rasagiline in Early Parkinson Disease: the TEMPO Study,&rdquo;",
"      <i>",
"       Arch Neurol",
"      </i>",
"      , 2002, 59(12):1937-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/13/24791/abstract-text/12470183/pubmed\" id=\"12470183\" target=\"_blank\">",
"        12470183",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parkinson Study Group, &ldquo;A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations. The PRESTO Study,&rdquo;",
"      <i>",
"       Arch Neurol",
"      </i>",
"      , 2005 62(2):241-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/13/24791/abstract-text/15710852/pubmed\" id=\"15710852\" target=\"_blank\">",
"        15710852",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rascol O, Brooks DJ, Melamed E et al, &ldquo;Rasagiline as an Adjunct to Levodopa in Patients with Parkinson&rsquo;s Disease and Motor Fluctuations (LARGO, Lasting effect in Adjunct therapy With Rasagiline Given Once Daily, Study): A Randomized, Double-Blind, Parallel-Group Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2005, 365(9463):947-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/13/24791/abstract-text/15766996/pubmed\" id=\"15766996\" target=\"_blank\">",
"        15766996",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman KI and Walker SE, &ldquo;A Reevaluation of Dietary Restrictions for Irreversible Monoamine Oxidase Inhibitors,&rdquo;",
"      <i>",
"       Psychiatr Ann",
"      </i>",
"      , 2001, 31(6):378-84.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman KI and Walker SE, &ldquo;Refining the MAOI Diet: Tyramine Content of Pizzas and Soy Products,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1999, 60(3):191-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/13/24791/abstract-text/10192596/pubmed\" id=\"10192596\" target=\"_blank\">",
"        10192596",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walker SE, Shulman KI, Tailor SA, et al, &ldquo;Tyramine Content of Previously Restricted Foods in Monoamine Oxidase Inhibitor Diets,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 1996, 16(5):383-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/13/24791/abstract-text/8889911/pubmed\" id=\"8889911\" target=\"_blank\">",
"        8889911",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10338 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-B1BE4F5CD0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_13_24791=[""].join("\n");
var outline_f24_13_24791=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985038\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14476718\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985062\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985104\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062199\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985105\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985106\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985118\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985040\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9780626\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985065\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3370799\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985076\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985071\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985072\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985083\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985082\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985086\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985066\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985067\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985069\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985070\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985107\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422183\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985110\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539974\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985089\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985090\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10338\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10338|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/45/18133?source=related_link\">",
"      Rasagiline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_13_24792="Prevention of acute graft-versus-host disease: Trials of T cell depletion";
var content_f24_13_24792=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of acute graft-versus-host disease: Trials of T cell depletion",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/13/24792/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/13/24792/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/13/24792/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/13/24792/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/13/24792/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/13/24792/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/13/24792/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically significant acute graft-versus-host disease (GVHD) occurs in 9 to 50 percent of patients who receive an allogeneic bone marrow graft from a genotypically HLA-identical sibling, despite intensive prophylaxis with immunosuppressive agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , corticosteroids, or antithymocyte globulin. Acute GVHD is also common in matched unrelated donors and in haploidentical related donors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Development of moderate (grade II) or severe (grade III or IV) acute GVHD after marrow transplantation is associated with a significant decrease in survival. Various methods to prevent GVHD have been developed. The mainstay of prophylaxis remains a combination of drugs that individually have been shown to prevent GVHD.",
"   </p>",
"   <p>",
"    This topic review will discuss the clinical trials that have evaluated T cell depletion for the PREVENTION of GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/1\">",
"     1",
"    </a>",
"    ]. The trials evaluating pharmacologic therapy and recommendations for the prevention and treatment of acute GVHD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42041?source=see_link\">",
"     \"Prevention of acute graft-versus-host disease: Trials of pharmacologic therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     T CELL DEPLETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;GVHD is primarily a T cell mediated disease. As such, one attractive approach to reduce the incidence of GVHD is to eliminate T lymphocytes from the donor inoculum prior to infusion of the bone marrow. This technique is effective in preventing acute GVHD across both major and minor histocompatibility barriers in mice. These early data in animal models led to many clinical trials in patients receiving bone marrow transplantation for leukemias (",
"    <a class=\"graphic graphic_table graphicRef73755 \" href=\"UTD.htm?10/33/10780\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Another potential advantage of T cell depletion is lowering the incidence of hepatic sinusoidal obstruction syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7081?source=see_link\">",
"     \"Treatment and prevention of hepatic sinusoidal obstruction syndrome following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, removal of T cells from donor bone marrow may have deleterious effects. T cell depletion adversely affects engraftment, the adequacy of immune reconstitution, and the incidence of leukemic relapse or infections. In addition, T cell depletion is associated with an increased risk of post-transplant lymphoproliferative disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=see_link&amp;anchor=H16931449#H16931449\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders\", section on 'Risk factors among HCT recipients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Methodologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several methods have been developed to deplete T lymphocytes from donor bone marrow. These include a variety of physical separation techniques such as density gradients, selective depletion with lectins, treatment with cytotoxic drugs, and the use of anti-T cell sera or monoclonal antibodies, either alone, with complement, or conjugated to toxins.",
"   </p>",
"   <p>",
"    Most studies use ex vivo treatment of the donor bone marrow with monoclonal antibodies. The most common methods include broadly reactive anti-T cell agents, such as anti-CD2, anti-CD3, and anti-CD5 antibodies, as well as agents with more restricted reactivity such as anti-CD8 antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/2-5\">",
"     2-5",
"    </a>",
"    ] and an anti-CD25 antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/6\">",
"     6",
"    </a>",
"    ]. A human antibody that is broadly reactive against lymphoid tissues,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    (Campath-1, anti-CD52), has also been used [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first human trials involved the addition of the monoclonal antibody to the harvested bone marrow. It was hoped that antibody-dependent cellular cytotoxicity, as well as human complement, would fix the antibody and cause cell lysis. These studies did not succeed.",
"   </p>",
"   <p>",
"    Subsequent studies utilized ex-vivo treatment with monoclonal antibodies and rabbit complement. Although these reports showed some efficacy, the amount of variability between batches of complement and the different antibodies led to the development of newer methods of T cell depletion. These methods include: antibodies bound to ricin A chain or other toxins; antibodies conjugated to magnetic beads; depletion of an antibody bound to target cells; soybean lectin; agglutination and E-rosette formation; and counterflow elutriation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Some studies have used a combination of methods [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These techniques usually achieve a 1.5 to 5 log reduction of T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/11\">",
"     11",
"    </a>",
"    ]. Unfortunately, as will be described below, most methods that reduce GVHD have been associated with an increase in either graft failure or disease relapse; as a result, there is no significant overall improvement in disease-free survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9523132\">",
"    <span class=\"h2\">",
"     Immunologic methods of separation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Alemtuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    (anti-CD52) has been used ex-vivo (on the graft) and in-vivo (in the recipient) in an attempt to deplete T cells and prevent GVHD. Alemtuzumab appears to decrease the rate of GVHD, but also increases time to engraftment.",
"   </p>",
"   <p>",
"    The largest study of ex-vivo T cell depletion with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    included 282 patients with leukemia treated with hematopoietic cell transplantation (HCT) from HLA-matched siblings [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/7\">",
"     7",
"    </a>",
"    ]. The incidence of grade II-IV GVHD was 12 percent; however, the incidence of graft failure was 15 percent. Graft failure was almost certainly due to graft rejection by residual",
"    <strong>",
"     recipient",
"    </strong>",
"    T cells which survived the conditioning protocol. In addition, the rate of relapse in patients with chronic myeloid leukemia (CML) was substantially above that reported in historical controls. The most important predictive factor for relapse appeared to be slow engraftment, consistent with the absence of a graft-versus-leukemia effect. An increased rate of relapse after HCT in CML also occurs with identical twin grafts, another setting in which the graft-versus-leukemia effect is absent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    has also been given to the recipient in-vivo, rather than to the graft ex-vivo, as part of a preparative regimen in an attempt to prevent GVHD. A case series of 22 patients evaluated the use of alemtuzumab in addition to other preparative therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/13\">",
"     13",
"    </a>",
"    ]. Most patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    plus a single dose of total body irradiation; four received oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    and intravenous cyclophosphamide. Alemtuzumab was administered at a daily dose of 5 mg on days -4, -3, -2, -1 and 0. No further GVHD prophylaxis was used. Grade II-IV acute GVHD occurred in four patients (19 percent) and there were no cases of graft failure. Similar results were noted in another report in which in vivo administration of alemtuzumab was associated with a reduced incidence of acute GVHD and a low rate of failure (9 percent); there was, however, a delay in neutrophil engraftment by up to seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have evaluated the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    , plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    (FMC) as an antibody-based minimal intensity conditioning regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link&amp;anchor=H15#H15\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Antibody-based minimal intensity conditioning'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 44 patients with various hematologic malignancies that used FMC as a conditioning regimen prior to HCT also administered cyclosporin for GVHD prophylaxis in the majority of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/17\">",
"       17",
"      </a>",
"      ]. No grade III-IV acute GVHD was noted and only one patient developed chronic GVHD. One of the 43 evaluable patients did not engraft; mixed chimerism was noted in 12 of the 30 patients in which this was studied.",
"     </li>",
"     <li>",
"      Another study of FMC conditioning in patients receiving transplants from matched unrelated donors compared results for the 107",
"      <span class=\"nowrap\">",
"       10/10",
"      </span>",
"      HLA-matched donors (MUD) and the 50 donors who were matched at 6 to 9 of the 10 HLA loci (MMUD) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/15\">",
"       15",
"      </a>",
"      ]. Graft failure rates were similar between the two groups (8 versus 3 percent), although rejection was more frequent in MMUDs (8 versus zero percent). There were no significant differences between donors in the incidences of grades II-IV acute GVHD (20 versus 22 percent), chronic extensive GVHD at three years (23 versus 24 percent), or treatment-related mortality at one year (27 percent for both).",
"     </li>",
"     <li>",
"      Another study evaluated different",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      doses (20 mg, 30 mg, 40 mg, and 60 mg) in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      as the conditioning regimen of 106 patients undergoing an HLA-identical sibling HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/16\">",
"       16",
"      </a>",
"      ]. When compared with higher doses of alemtuzumab, the 20 mg dose was associated with a greater risk of severe GVHD. In contrast, when compared with higher doses, the 30 mg dose had similar rates of severe GVHD and other clinical endpoints, but better lymphocyte recovery.",
"     </li>",
"     <li>",
"      In a study in 24 consecutive patients with aplastic anemia, prevention of GVHD with an",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      -based regimen, in comparison with treatment with calcineurin inhibitors and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , resulted in a significant reduction in the incidence of acute and chronic GVHD with no significant differences in time to engraftment or graft failure [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/18\">",
"       18",
"      </a>",
"      ]. A significantly higher proportion of alemtuzumab-treated patients developed CMV reactivation compared to control patients; none developed CMV disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the concern about graft rejection with T cell depletion, the use of both ex-vivo and in vivo",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    was evaluated in 70 patients with acute myeloid leukemia in first remission [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/19\">",
"     19",
"    </a>",
"    ]. No posttransplant immunosuppression was given and the results were compared with two control groups: 50 patients who received only bone marrow depleted by alemtuzumab, and 459 registry patients who received nondepleted grafts and were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    GVHD prophylaxis. Compared to the registry group, the treatment group had significant reductions in the incidence of acute GVHD (4 versus 35 percent) and chronic GVHD (3 versus 36 percent); there was no difference in leukemia relapse at five years between the two groups (30 versus 29 percent), and only 6 percent of treated patients had graft rejection. Despite these benefits, there was no difference in five-year survival between the two groups (62 versus 58 percent). The second control group receiving only marrow depletion by alemtuzumab generally had worse outcomes than the other two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9522804\">",
"    <span class=\"h2\">",
"     Physical separation techniques",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Selective CD6+ cell depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another approach to the prevention of GVHD is depletion of CD6+ T lymphocytes from donor bone marrow. CD6+ cell depletion selectively targets mature T cells but spares closely related and potentially important cells such as NK (natural killer) cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One report evaluating this approach consisted of 41 adults with acute leukemia in first remission undergoing HCT from HLA-identical",
"    <strong>",
"     sibling",
"    </strong>",
"    donors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/21\">",
"     21",
"    </a>",
"    ]. The bone marrows were treated ex vivo with three rounds of incubation with an anti-CD6 monoclonal antibody (anti-T12) and rabbit complement. Patients did not receive any other prophylactic treatment for acute GVHD. Engraftment occurred in all but one patient. The estimated incidence of acute GVHD was 15 percent; chronic GVHD developed in five patients, all of whom had acute GVHD. The treatment-related mortality at day +100 was 5 percent and there was no excessive toxicity. This protocol resulted in a 1.5 to 2 log depletion of marrow T lymphocytes which could have been sufficient to decrease the occurrence and severity of acute GVHD and, at the same time, permit early reconstitution because of the sparing of NK cells.",
"   </p>",
"   <p>",
"    A second report consisted of 48 adults with hematologic malignancies who received allogeneic HCT from",
"    <strong>",
"     unrelated",
"    </strong>",
"    donors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/22\">",
"     22",
"    </a>",
"    ]. Recipients received ablation therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , total body irradiation, and total nodal irradiation. Donor marrow was depleted of CD6+ T cells with anti-T12 antibody; no other anti-GVHD prophylaxis was given. All 48 patients engrafted, with no late graft failures. The incidence of grades II-IV acute GVHD was 42 percent, and mortality at day +100 was 19 percent.",
"   </p>",
"   <p>",
"    The effects of anti-CD6 antibodies on marrow function have been compared in vitro to a mixture of eight antibodies previously used for clinical trials in Seattle; the latter antibodies had been associated with a higher incidence of graft failure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment with the eight antibody mixture produced a greater than 3 log depletion for precursors of interleukin (IL)-2 producing cells and approximately 1 log depletion of precursors for NK cells.",
"     </li>",
"     <li>",
"      Treatment with anti-CD6 produced approximately 1 log depletion of precursors for IL-2 producing cells but had no effect on NK precursors.",
"     </li>",
"     <li>",
"      Compared to administration of the antibody mixture, bone marrow cells remaining after anti-CD6 treatment had more cytotoxic activity when cultured in IL-2 during the first 6 days of culture but similar cytotoxicity activity after 10 days in culture.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The data lead to the suggestion that the more extensive depletion of T cells and NK cells produced by the eight antibody mixture could have been responsible for the higher incidence of graft failure. Thus, it appears that the number of clonogenic T cells present in the graft after T cell depletion correlates with the development of GVHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Soybean lectin and E-rosetting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another method of T cell depletion has been by two step soybean lectin agglutination and E-rosetting with sheep red blood cells, which achieves a 2.5 to 3 log depletion of clonable T lymphocytes. Unfortunately, graft rejection remains a serious limitation to the success of this form of GVHD prophylaxis with graft failure occurring in approximately 16 percent of patients.",
"   </p>",
"   <p>",
"    This approach was evaluated in a series of 31 adults with acute nonlymphocytic leukemia in first remission receiving related HLA and MLC (mixed lymphocyte culture) compatible bone marrows [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/10,24\">",
"     10,24",
"    </a>",
"    ]. No additional prophylaxis for acute GVHD was used following T cell depletion. Five patients suffered immune-mediated graft rejection, while only two had grade II acute GVHD that were limited to the skin and resolved promptly following treatment with steroids. Clinically apparent chronic GVHD did not occur. All patients had 100 percent performance status without further immunosuppressive therapy.",
"   </p>",
"   <p>",
"    The same group reported the results in 39 consecutive patients with AML treated with the same T cell depletion regimen.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35414?source=see_link\">",
"     Thiotepa",
"    </a>",
"    was added to the preparatory regimen in an attempt to decrease the incidence of graft rejection and patients at high risk for rejection also received antithymocyte globulin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    . There were no cases of immune-mediated graft rejection and no cases of grade II-IV GVHD. Disease-free survival was 77 percent for those in first remission and 50 percent for those in second remission [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     E-rosetting and CD34+ cell selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of T cell depletion by E-rosetting with sheep erythrocytes cells followed by CD34+ selection with an immunoadsorption column was evaluated in one study of 43 patients with high risk acute leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/26\">",
"     26",
"    </a>",
"    ]. Full engraftment was achieved in all patients and none of the patients who could be evaluated developed acute or chronic GVHD. The major problem, as with any method that reduces GVHD (and therefore graft-versus-leukemia), was relapse of leukemia, which occurred in 11 of 23 with acute lymphoblastic leukemia and 2 of 20 with acute myeloid leukemia. The 18-month disease-free survival was 28 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25129?source=see_link\">",
"     \"Overview of hematopoiesis and stem cell function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Counterflow elutriation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another method of T cell depletion is the use of counterflow centrifugal elutriation. In one study, 80 consecutive patients were transplanted with HLA-identical sibling marrows for leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/27\">",
"     27",
"    </a>",
"    ]. The donor marrow was depleted of lymphocytes by counterflow centrifugation, and the patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    alone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    alone, or both. The probability of grade II-IV acute GVHD was 15 percent. However, relapse was a problem, particularly in patients with CML in chronic phase. The overall the disease-free survival after transplantation for these acute leukemias is not different from data reported at other centers using unmanipulated bone marrow.",
"   </p>",
"   <p>",
"    The second study involved 23 patients who received lymphocyte-depleted bone marrow allografts from HLA identical, MLC nonreactive sibling donors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/9\">",
"     9",
"    </a>",
"    ]. A standard dose of 5 x 10",
"    <sup>",
"     5",
"    </sup>",
"    <span class=\"nowrap\">",
"     lymphocytes/kg",
"    </span>",
"    was given using counterflow centrifugal elutriation. Patients were maintained on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    immunosuppression for 170 days after HCT. None of the patients developed severe acute GVHD, and 22 patients had prompt recovery of hematopoietic function. Thus, engineered grafts with counterflow centrifugal elutriation result in a low incidence of GVHD and a relatively low incidence of graft failure if additional immunosuppressive agents are given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     T CELL DOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose or number of T cells infused is likely to be important. Although extensive T cell depletion of the marrow graft produces a marked decrease in the incidence and severity of acute and chronic GVHD, it is also associated with a significantly higher incidence of graft failure and relapse of the underlying disease.",
"   </p>",
"   <p>",
"    One study attempted to find an optimal T cell dose that avoids the extreme risks on both sides by administering a fixed low number of T cells, 1 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      5",
"     </sup>",
"     /kg,",
"    </span>",
"    from HLA-identical siblings [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/28\">",
"     28",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    was given after transplantation. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Engraftment occurred in all patients",
"     </li>",
"     <li>",
"      There were no graft rejections",
"     </li>",
"     <li>",
"      Eight of 30 evaluable patients developed grade II GVHD, which was limited to the skin in all cases",
"     </li>",
"     <li>",
"      Relapse was observed in one of 13 leukemic transplant recipients",
"     </li>",
"     <li>",
"      Chronic GVHD, also limited to the skin, occurred in one-third of evaluable patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar finding were noted in another series in which none of 24 patients who received less than 10",
"    <sup>",
"     5",
"    </sup>",
"    T",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    developed acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These studies suggest that a definable low number of T cells can allow the graft to \"take\" and, at the same time, prevent severe GVHD. However, the contribution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    after transplantation in the first study cannot be ascertained.",
"   </p>",
"   <p>",
"    The potential importance of posttransplant immunosuppression was illustrated in a study of 14 children in which donor bone marrows were T cell depleted and a T cell addback was performed from the donor's peripheral blood [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/29\">",
"     29",
"    </a>",
"    ]. The median number of CD3+ cells in this study was 2.6 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      5",
"     </sup>",
"     /kg",
"    </span>",
"    recipient weight, higher than the 1 x 10",
"    <sup>",
"     5",
"    </sup>",
"    described above in adults. These children were not given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . All children engrafted and there were no late graft rejections; however, acute GVHD developed in nine, with two having grade IV GVHD.",
"   </p>",
"   <p>",
"    These findings indicated that a high incidence of GVHD can occur in spite of infusion of low numbers of T cells when postgraft immunosuppression is not utilized. At least in children, 2.6 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      5",
"     </sup>",
"     /kg",
"    </span>",
"    CD3+ cells are too many in the absence of immunosuppression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     T CELL DEPLETION VERSUS PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been two studies comparing T cell depletion to pharmacologic therapy for the prevention of GVHD. In a prospective randomized trial, 48 adults transplanted for leukemia were treated with T cell depletion or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , the most commonly utilized drug prophylaxis regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42041?source=see_link\">",
"     \"Prevention of acute graft-versus-host disease: Trials of pharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The T cell depletion method utilized was an anti-CD8 and an anti-CD6 antibody plus complement. All patients engrafted except for one who had an early death following transplantation. Patients receiving T cell depleted marrow had a faster time to engraftment but a higher incidence of grade II-IV acute GVHD (23 versus 12 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ). There was no difference in leukemia-free survival (42 and 44 percent at three years). Five-year follow-up suggested that T cell depletion might be associated with a worse outcome in patients with CML but not acute leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An adverse effect of T cell depletion in HCT for CML was also noted in a second nonrandomized series, which compared three regimens &mdash;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    alone, T cell depletion with Campath-1, and the combination of cyclosporine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    &mdash; in 140 consecutive patients with CML [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/32\">",
"     32",
"    </a>",
"    ]. T cell depletion was associated with a lower disease-free survival at two years (40 versus 68 percent with cyclosporine) and a higher rate of hematologic relapse (41 versus 6 percent).",
"   </p>",
"   <p>",
"    A multi-center randomized trial compared two regimens: T cell depletion (using two different methods) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    versus cyclosporine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    in over 400 evaluable patients receiving unrelated bone marrow transplantation for lymphohematopoietic malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In this study T cell depletion was only partial (1 log) and all patients received cyclosporine. T cell depletion was associated with a significantly lower incidence of grade III-IV acute GVHD (18 versus 37 percent), but no significant difference in chronic GVHD (29 versus 34 percent), transplant-related mortality, or three-year disease-free survival. Subjects receiving T cell depleted grafts had a higher risk of chronic myeloid leukemia relapse (20 versus 9 percent) and a higher risk of cytomegalovirus infection (28 versus 17 percent). These data suggest that there are many competing causes for transplantation failure. Reduction of acute GVHD alone (eg, without a change in the incidence of chronic GVHD) may not be sufficient for better overall survival, due to higher relapse and infectious complications, reflecting the all-important balance between the deleterious effects of acute and chronic GVHD and the beneficial graft-versus-leukemia effect.",
"   </p>",
"   <p>",
"    In a retrospective analysis comparing T cell depletion to pharmacologic therapy in patients with various hematologic diseases undergoing unrelated donor transplantation, there were no differences in the incidence of acute or chronic GVHD, relapse, or overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of donor T cells expressing the herpes simplex thymidine kinase could allow, if GVHD were to occur, selective in vivo depletion of these T cells by the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     \"Ganciclovir: Drug information\"",
"    </a>",
"    .) Preliminary results of a phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    trial in 12 patients receiving T cell depleted allogeneic HCT have indicated the feasibility of this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An interesting approach for minimizing acute GVHD while maintaining the graft versus tumor effect was explored in 37 subjects undergoing allogeneic transplantation by taking advantage of the relative insensitivity to radiation of the immune system's regulatory T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/39\">",
"     39",
"    </a>",
"    ]. Host natural killer T cells, which are known to modulate the proliferation and cytokine secretion of donor T cells involved in the acute GVHD response, were relatively increased by giving total lymphoid irradiation over a period of 10 consecutive days along with antithymocyte globulin. Following transplantation of G-CSF-mobilized donor peripheral blood mononuclear cells along with cyclosporin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, the following major findings included [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24792/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite 38 percent of the transplants being from unrelated donors, a situation in which a high incidence of acute GVHD would have been expected, clinically significant (grade 2 to 4) acute GVHD was experienced in only one of the 37 subjects (3 percent)",
"     </li>",
"     <li>",
"      Among the 33 subjects surviving more than 100 days, limited and extensive chronic GVHD was noted in two and seven subjects, respectively, for a total incidence of 27 percent.",
"     </li>",
"     <li>",
"      Antitumor effects were shown by the change from partial to complete remission in 12 of 18 patients with lymphoid malignant diseases, as well as the observation of tumor responses in areas outside of the field of the total lymphoid irradiation",
"     </li>",
"     <li>",
"      At a median followup of &gt;400 days, 27 of the 37 patients (73 percent) were still alive",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional experience with this novel approach is eagerly awaited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103574181\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Graft-versus-host disease (GVHD) occurs when immune cells transplanted from a non-identical donor (the graft) recognize the transplant recipient (the host) as foreign, thereby initiating an immune reaction that causes disease in the transplant recipient.",
"     </li>",
"     <li>",
"      GVHD is primarily a T cell mediated disease. As such, one attractive approach to reduce the incidence of GVHD is to eliminate T lymphocytes from the donor inoculum prior to infusion of the bone marrow. Unfortunately, most methods that reduce GVHD have been associated with an increase in graft failure, delayed immune reconstitution, disease relapse, and post-transplant lymphoproliferative disorder; as a result, there is no significant overall improvement in disease-free survival. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'T cell depletion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several methods have been developed to deplete T lymphocytes from donor bone marrow:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Physical separation techniques include density gradients, selective depletion with lectins, treatment with cytotoxic drugs, and the use of anti-T cell sera or monoclonal antibodies, either alone, with complement, or conjugated to toxins. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Counterflow elutriation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Soybean lectin and E-rosetting'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Selective CD6+ cell depletion'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'E-rosetting and CD34+ cell selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ex-vivo treatment of the donor bone marrow with monoclonal antibodies with broad reactivity (eg, anti-CD2, anti-CD3, and anti-CD5 antibodies) or more restricted reactivity (eg, anti-CD8 and anti-CD25). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Methodologies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In-vivo T cell depletion of the recipient or ex-vivo T cell depletion of the graft with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      (ie, anti-CD52). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Alemtuzumab'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although extensive T cell depletion of the marrow graft produces a marked decrease in the incidence and severity of acute and chronic GVHD, it is also associated with a significantly higher incidence of graft failure and relapse of the underlying disease. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'T cell dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When compared with pharmacologic prophylaxis for GVHD alone, T cell depletion is associated with a significantly lower incidence of grade III-IV acute GVHD, but no significant difference in chronic GVHD, transplant-related mortality, or disease-free survival. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'T cell depletion versus pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/1\">",
"      Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001; 98:3192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/2\">",
"      Prentice HG, Blacklock HA, Janossy G, et al. Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet 1984; 1:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/3\">",
"      Mitsuyasu RT, Champlin RE, Gale RP, et al. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial. Ann Intern Med 1986; 105:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/4\">",
"      Filipovich AH, McGlave PB, Ramsay NK, et al. Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone-marrow transplantation. Lancet 1982; 1:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/5\">",
"      Antin JH, Bierer BE, Smith BR, et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991; 78:2139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/6\">",
"      Solomon SR, Mielke S, Savani BN, et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005; 106:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/7\">",
"      Hale G, Cobbold S, Waldmann H. T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation. Transplantation 1988; 45:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/8\">",
"      Reisner Y, Kapoor N, O'Reilly RJ, Good RA. Allogeneic bone marrow transplantation using stem cells fractionated by lectins: VI, in vitro analysis of human and monkey bone marrow cells fractionated by sheep red blood cells and soybean agglutinin. Lancet 1980; 2:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/9\">",
"      Wagner JE, Santos GW, Noga SJ, et al. Bone marrow graft engineering by counterflow centrifugal elutriation: results of a phase I-II clinical trial. Blood 1990; 75:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/10\">",
"      Kernan NA, Collins NH, Juliano L, et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 1986; 68:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/11\">",
"      Debelak J, Shlomchik MJ, Snyder EL, et al. Isolation and flow cytometric analysis of T-cell-depleted CD34+ PBPCs. Transfusion 2000; 40:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/12\">",
"      Gale RP, Horowitz MM, Ash RC, et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994; 120:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/13\">",
"      Willemze R, Richel DJ, Falkenburg JH, et al. In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation. Bone Marrow Transplant 1992; 9:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/14\">",
"      Hale G, Waldmann H. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant 1994; 13:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/15\">",
"      Mead AJ, Thomson KJ, Morris EC, et al. HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. Blood 2010; 115:5147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/16\">",
"      Chakraverty R, Orti G, Roughton M, et al. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood 2010; 116:3080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/17\">",
"      Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/18\">",
"      Siegal D, Xu W, Sutherland R, et al. Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies. Bone Marrow Transplant 2008; 42:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/19\">",
"      Hale G, Zhang MJ, Bunjes D, et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998; 92:4581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/20\">",
"      Soiffer RJ, Murray C, Mauch P, et al. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol 1992; 10:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/21\">",
"      Soiffer RJ, Fairclough D, Robertson M, et al. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood 1997; 89:3039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/22\">",
"      Soiffer RJ, Weller E, Alyea EP, et al. CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol 2001; 19:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/23\">",
"      Voltarelli JC, Corpuz S, Martin PJ. In vitro comparison of two methods of T cell depletion associated with different rates of graft failure after allogeneic marrow transplantation. Bone Marrow Transplant 1990; 6:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/24\">",
"      Young JW, Papadopoulos EB, Cunningham I, et al. T-cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. Blood 1992; 79:3380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/25\">",
"      Papadopoulos EB, Carabasi MH, Castro-Malaspina H, et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998; 91:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/26\">",
"      Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/27\">",
"      Schattenberg A, De Witte T, Preijers F, et al. Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation. Blood 1990; 75:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/28\">",
"      Verdonck LF, de Gast GC, van Heugten HG, Dekker AW. A fixed low number of T cells in HLA-identical allogeneic bone marrow transplantation. Blood 1990; 75:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/29\">",
"      Potter MN, Pamphilon DH, Cornish JM, Oakhill A. Graft-versus-host disease in children receiving HLA-identical allogeneic bone marrow transplants with a low adjusted T lymphocyte dose. Bone Marrow Transplant 1991; 8:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/30\">",
"      Ringd&eacute;n O, Pihlstedt P, Markling L, et al. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991; 7:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/31\">",
"      Ringd&eacute;n O, Remberger M, Aschan J, et al. Long-term follow-up of a randomized trial comparing T cell depletion with a combination of methotrexate and cyclosporine in adult leukemic marrow transplant recipients. Transplantation 1994; 58:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/32\">",
"      Marks DI, Hughes TP, Szydlo R, et al. HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome. Br J Haematol 1992; 81:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/33\">",
"      Wagner JE, Thompson JS, Carter SL, et al. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 2005; 366:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/34\">",
"      Pavletic SZ, Carter SL, Kernan NA, et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood 2005; 106:3308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/35\">",
"      Lee SJ, Zahrieh D, Alyea EP, et al. Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. Blood 2002; 100:2697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/36\">",
"      Tiberghien P, Ferrand C, Lioure B, et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 2001; 97:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/37\">",
"      Cohen JL, Boyer O, Klatzmann D. Suicide gene therapy of graft-versus-host disease: immune reconstitution with transplanted mature T cells. Blood 2001; 98:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/38\">",
"      Marktel S, Magnani Z, Ciceri F, et al. Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 2003; 101:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24792/abstract/39\">",
"      Lowsky R, Takahashi T, Liu YP, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 2005; 353:1321.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3544 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-40244E071D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_13_24792=[""].join("\n");
var outline_f24_13_24792=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H103574181\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      T CELL DEPLETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Methodologies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9523132\">",
"      Immunologic methods of separation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Alemtuzumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9522804\">",
"      Physical separation techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Selective CD6+ cell depletion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Soybean lectin and E-rosetting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - E-rosetting and CD34+ cell selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Counterflow elutriation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      T CELL DOSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      T CELL DEPLETION VERSUS PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EXPERIMENTAL APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103574181\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/3544\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3544|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/33/10780\" title=\"table 1\">",
"      T cell depletion prevent GVHD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=related_link\">",
"      Ganciclovir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25129?source=related_link\">",
"      Overview of hematopoiesis and stem cell function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=related_link\">",
"      Prevention and treatment of acute graft-versus-host disease: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42041?source=related_link\">",
"      Prevention of acute graft-versus-host disease: Trials of pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7081?source=related_link\">",
"      Treatment and prevention of hepatic sinusoidal obstruction syndrome following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_13_24793="Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)";
var content_f24_13_24793=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/13/24793/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/13/24793/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/13/24793/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/13/24793/contributors\">",
"     Mark S Link, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/13/24793/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/13/24793/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/13/24793/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 19, 2009.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular nodal reentrant tachycardia (AVNRT) is one of the common supraventricular tachycardias (SVTs). As with the majority of SVTs, the QRS complex in AVNRT is usually narrow (ie, &le;120 msec), reflecting normal ventricular activation through the His-Purkinje system. Because of its abrupt onset and termination, AVNRT is categorized among the paroxysmal SVTs (PSVTs). It is the most common of the PSVTs, accounting for nearly two-thirds of cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'Paroxysmal SVT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are a number of synonyms for AVNRT, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      AV junctional reentrant tachycardia",
"     </li>",
"     <li>",
"      Reciprocal or reciprocating AV nodal reentrant tachycardia",
"     </li>",
"     <li>",
"      Junctional reciprocating tachycardia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This card will review the clinical manifestations, the electrophysiologic and electrocardiographic characteristics, and a general approach to the management of AVNRT. A detailed discussion of catheter ablation for AVNRT and of the broader approach to narrow QRS complex tachycardias are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=see_link\">",
"     \"Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiologic substrate for AVNRT involves dual electrical pathways in or near the AV node. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Dual AV nodal physiology'",
"    </a>",
"    below.) Structural heart disease is not necessary for the development of AVNRT. The arrhythmia usually develops in hearts that are otherwise normal, although it can also occur in the presence of organic heart disease.",
"   </p>",
"   <p>",
"    There is often no apparent precipitating cause for episodes of AVNRT. However, in some patients, nicotine, alcohol, stimulants, exercise, or surges in vagal tone can initiate episodes. Familial AVNRT has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms associated with arrhythmia episodes are nonspecific. The nature and severity of symptoms are often influenced by the rate of the tachycardia. Because of the paroxysmal nature of the arrhythmia, the onset and termination of the symptoms are usually sudden.",
"   </p>",
"   <p>",
"    Patients most commonly complain of palpitations, an odd feeling in the chest, and, on occasion, lightheadedness. Those with significant heart disease may have additional symptoms such as dyspnea and chest pain. Some patients with AVNRT have a feeling of polyuria and experience a diuresis during or after AVNRT; the mechanism probably is related to an elevated mean right atrial pressure and plasma level of atrial natriuretic peptide which are present during the arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a series of 167 SVT patients referred for radiofrequency ablation, the 64 patients with AVNRT reported the following symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Palpitations - 98 percent",
"     </li>",
"     <li>",
"      Dizziness - 78 percent",
"     </li>",
"     <li>",
"      Dyspnea - 47 percent",
"     </li>",
"     <li>",
"      Chest pain - 38 percent",
"     </li>",
"     <li>",
"      Fatigue - 19 percent",
"     </li>",
"     <li>",
"      Syncope - 16 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As demonstrated in this series, syncope is an uncommon feature of AVNRT. Syncope appears to be more likely with high heart rates, and in this series the only independent predictor for syncope was a heart rate &ge;170",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"    However, factors other than heart rate also contribute to syncope. As an example, abnormal vasomotor adaptation during AVNRT has been reported, suggesting a role for neurally mediated (neurocardiogenic) responses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In rare cases, AVNRT deteriorates into ventricular fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;AVNRT can present at any age but, as with AV reentrant tachycardia (AVRT, also known as accessory pathway-mediated tachycardia), it is more likely to begin in young adults. In a series of 231 patients with AVNRT, the mean age of symptom onset was 32 years, with two-thirds of cases beginning after the age of 20 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The electrophysiologic characteristics of the AV node can evolve over time, resulting in changes in the frequency and characteristics of the tachycardia. This evolution was illustrated in a series of 113 patients with either AVNRT or AVRT who did not undergo ablation, but had repeat EP studies 5 and 10 years after a baseline study [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/8\">",
"     8",
"    </a>",
"    ]. Although dual AV node pathway physiology persisted in most AVNRT patients, the following alterations occurred:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The refractory periods of both the fast and slow pathways increased.",
"     </li>",
"     <li>",
"      The incidence of retrograde conduction through the AV node decreased.",
"     </li>",
"     <li>",
"      The cycle length of induced AVNRT increased.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although 90 percent of AVNRT patients still had inducible tachycardias at follow-up study, the beta-agonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    was more frequently required to elicit the arrhythmia. Thus, these results are consistent with the clinical finding that many patients will have fewer clinical events over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ELECTROPHYSIOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;AVNRT is a reentrant rhythm that utilizes the AV node and, usually, perinodal atrial tissue (",
"    <a class=\"graphic graphic_table graphicRef53347 \" href=\"UTD.htm?6/56/7052\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. A more detailed discussion of the electrophysiology of AVNRT can be found in published reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/9-12\">",
"     9-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dual AV nodal physiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The simplest concept of AV nodal physiology that allows for reentry involves separate electrical pathways within or proximal to the AV node. This model is supported by clinical observations as well as animal and human mapping studies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/9,13\">",
"     9,13",
"    </a>",
"    ]. These pathways may be distinct anatomic structures, or may be functionally separate (ie, regions that appear anatomically continuous, but have different electrical properties). Whether the dual pathways are anatomic or functional, in order for reentry to occur, they must have different conduction velocities and refractory periods [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One pathway conducts rapidly and has a relatively long refractory period. This is called the fast or beta pathway.",
"     </li>",
"     <li>",
"      The second pathway conducts relatively slowly and has a shorter refractory period. This is called the slow or alpha pathway.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The origins of the fast and slow pathways are probably in perinodal atrial tissue. These pathways join and enter a final common pathway in the AV node. While atrial tissue above the AV node appears to be part of the reentrant circuit, the bundle of His below the node is probably",
"    <strong>",
"     not",
"    </strong>",
"    a necessary part of the circuit. This can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AVNRT is associated with 2:1 AV block in approximately 10 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/15\">",
"       15",
"      </a>",
"      ]. With this form of block, the completion of two complete circuits is evidenced by two retrograde P waves while only one of the impulses traverses the His bundle on the way to the ventricles. Thus, the bundle of His is not a required component of the circuit. The AV block in this setting is probably a functional infranodal block within the bundle of His [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      His bundle electrograms indicate that reentry is proximal to the recording site [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Dual pathways during normal sinus rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;During normal sinus rhythm, AV conduction occurs as follows (",
"    <a class=\"graphic graphic_figure graphicRef79760 \" href=\"UTD.htm?1/35/1598\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The normal sinus beat enters the AV node and the impulse travels down both the fast and slow pathways.",
"     </li>",
"     <li>",
"      The impulse traveling down the fast pathway reaches the His bundle first creating a refractory wake.",
"     </li>",
"     <li>",
"      The impulse traveling down the slow pathway is extinguished when, in the area of the final common pathway, it runs into the refractory wake of the impulse that had traveled down the fast pathway.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact anatomic distribution of these pathways is uncertain. Koch's triangle is bounded by the tricuspid ring and the tendon of Todoro, which bracket the coronary sinus at the base of the triangle and are in close proximity forming the apex near the His bundle at the membranous septum. As an approximation, Koch's triangle can be divided into thirds: the anterior, which contains the compact AV node and the fast pathways; the middle; and the posterior, which is associated with the coronary sinus (",
"    <a class=\"graphic graphic_figure graphicRef69647 \" href=\"UTD.htm?12/17/12562\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The anatomic location of these pathways was evaluated with high resolution mapping in a series of patients with both the common form and uncommon forms of AVNRT (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Common form of the arrhythmia'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12\">",
"     'Uncommon forms'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/9\">",
"     9",
"    </a>",
"    ]. In these maps, retrograde fast pathway conduction caused earliest atrial activation at the apex of Koch's triangle in the vicinity of the junction between the AV node and the bundle of His. Retrograde slow pathway conduction during the uncommon fast-slow form of AVNRT activates the atrium earliest in the lower (most frequent) or middle portion of Koch's triangle near the inferior portion of the coronary sinus ostium. Therefore, the perinodal atrium, extending from bundle of His site to the inferior portion of the coronary sinus ostium, is an integral part of the reentry circuit [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Model limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all patients with AVNRT have evidence of dual pathways during EP studies. Conversely, not all patients with dual AV nodal pathways have clinical AVNRT (",
"    <a class=\"graphic graphic_waveform graphicRef60369 graphicRef72161 \" href=\"UTD.htm?34/2/34858\">",
"     waveform 1A-B",
"    </a>",
"    ). The imperfect association between dual AV nodal physiology and clinical AVNRT was illustrated in a series of 180 patients undergoing EP studies for a variety of indications [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/19\">",
"     19",
"    </a>",
"    ]. Among the 87 patients with AVNRT, 39 percent did not have clear evidence of dual AV nodal physiology. In contrast, 30 percent of the 66 patients with documented dual AV nodal physiology did not have AVNRT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3097?source=see_link\">",
"     \"Invasive cardiac electrophysiology studies: Tachyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, the anatomic and electrophysiologic mechanism of AVNRT may be more complex than the dual AV nodal physiology model suggests [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Based on optical mapping studies in normal dogs, there appear to be multiple nondiscrete atrial inputs to the AV node, with a transitional zone surrounding the AV node that is asymmetric; the transitional zone is important in delaying AV nodal conduction and in allowing an excitable gap [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/20\">",
"     20",
"    </a>",
"    ]. The nondiscrete pathways can be arbitrarily divided into fast, intermediate, and slow pathways based on conduction velocities. Unidirectional block occurring in the transitional zone can transform the nondiscrete pathways model into a classic dual pathways physiology for AVNRT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Common form of the arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 80 to 90 percent of patients with AVNRT present with what is called the common form of the arrhythmia. The common form is also called \"typical AVNRT\" or \"slow-fast\" AVNRT.",
"   </p>",
"   <p>",
"    This form of AVNRT usually initiates as follows (",
"    <a class=\"graphic graphic_figure graphicRef79760 \" href=\"UTD.htm?1/35/1598\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A premature atrial beat (or less commonly, a premature junctional or ventricular beat with retrograde conduction) arrives at the AV node when the fast pathway is in its refractory period. Thus, antegrade conduction down the fast pathway is blocked.",
"     </li>",
"     <li>",
"      If the premature beat arrives in a specific time window (ie a \"critically timed\" premature beat), the slow pathway, with a shorter refractory period than the fast pathway, would have recovered excitability.",
"     </li>",
"     <li>",
"      The premature beat conducts via the slow pathway, through the final common pathway, to the bundle of His. As a result, the PR interval of the premature beat will be longer than those of normal beats conducted through the fast pathway.",
"     </li>",
"     <li>",
"      If the fast pathway has recovered its excitability by the time the slow pathway impulse reaches the distal junction of the two pathways, the impulse can conduct retrograde up the fast pathway. The circuit may then become repetitive with antegrade conduction back down the slow pathway and retrograde conduction up the fast pathway resulting in a sustained tachycardia (",
"      <a class=\"graphic graphic_figure graphicRef79760 \" href=\"UTD.htm?1/35/1598\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef50122 \" href=\"UTD.htm?42/30/43501\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This proposed mechanism explains a number of clinical observations in AVNRT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single premature atrial beat (or retrograde penetration of the AV node from a junctional or ventricular premature beat) can initiate the arrhythmia.",
"     </li>",
"     <li>",
"      Penetration of the reentrant circuit by a premature beat can abruptly terminate the arrhythmia.",
"     </li>",
"     <li>",
"      A train of paced impulses at a rate faster than the spontaneous arrhythmia can gain control of the reentrant pathway and accelerate the arrhythmia, a phenomenon called",
"      <strong>",
"       entrainment",
"      </strong>",
"      . Entrainment followed by the cessation of pacing can be used to terminate the arrhythmia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A concealed atriohisian tract that bypasses the AV node may constitute the retrograde fast pathway in up to a third of all apparently \"typical\" AVNRT cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Uncommon forms",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 20 percent of AVNRT patients have uncommon, or atypical, forms of the arrhythmia. As an example, antegrade conduction can occur down the fast pathway with retrograde conduction up the slow pathway (",
"    <a class=\"graphic graphic_figure graphicRef56806 \" href=\"UTD.htm?22/16/22799\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef66828 \" href=\"UTD.htm?31/31/32240\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef81639 \" href=\"UTD.htm?38/48/39690\">",
"     waveform 2",
"    </a>",
"    ). In addition, some patients have multiple slow pathways, and in slow-slow variants of AVNRT both the antegrade and retrograde limbs of the circuit utilize slow AV nodal pathways.",
"   </p>",
"   <p>",
"    At times, coronary sinus activation may be involved. In a study of 360 AVNRTs, there were 23 atypical AVNRTs (6 percent consisting of 11 fast-slow and 12 slow-slow) in 18 patients who exhibited eccentric coronary sinus activation with the earliest retrograde atrial activation approximately 11 mm inside the coronary sinus [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an uncommon form AVNRT, conduction through the reentrant circuit is so slow that the HR is less than 100 bpm. Despite the absence of tachycardia, patients can be symptomatic and may be treated with a slow pathway ablation. This arrhythmia, sometimes referred to as AV nodal reentrant arrhythmia (AVNRA), has been mistaken for a junctional rhythm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'Undetectable P waves'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=see_link\">",
"     \"Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Effect of enhanced vagal tone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased vagal tone can cause termination of AVNRT by slowing antegrade conduction in the slow pathway and causing retrograde conduction block in the fast pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/24\">",
"     24",
"    </a>",
"    ]. These responses are the basis of the use of vagal maneuvers such as carotid sinus massage or the Valsalva maneuver to terminate AVNRT. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Acute termination'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/46/21224?source=see_link\">",
"     \"Vagal maneuvers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, increased vagal tone may also facilitate the induction of AVNRT in some circumstances. In a series of 10 patients with AVNRT, electrophysiologic data were measured before and during continuous enhancement of vagal tone induced by infusing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/25\">",
"     25",
"    </a>",
"    ]. Vagal enhancement markedly prolonged the effective refractory period and functional refractory period of antegrade conduction in the fast pathway. However, the refractoriness of antegrade conduction in the slow pathway and retrograde conduction in the fast pathway were unchanged.",
"   </p>",
"   <p>",
"    Such changes are conducive to induction of the common form of AVNRT with a premature atrial complex as described above. These findings may explain why some patients experience the onset of AVNRT during sleep or after sudden bending forward or squatting, all of which can enhance vagal tone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Gender differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a cohort of 203 patients undergoing EP study and ablation for AVNRT, there were significant differences in the electrophysiologic properties of the slow pathways between women and men [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/26\">",
"     26",
"    </a>",
"    ]. Women, who outnumbered men 2:1 in this series, had slow pathways with shorter refractory periods (258 versus 287 msec in men), and tachycardias with shorter cycle lengths (354 versus 383 msec). There was no difference in the refractory periods of the fast pathways. Thus, women had a greater difference between the refractory periods of the slow and fast pathways, which may have contributed to both the higher incidence and more rapid tachycardias in women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Age differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a retrospective study of 350 patients who underwent radiofrequency ablation for AVNRT, patients over 65 years of age had a higher prevalence of structural heart disease, longer A-H and H-V intervals, and a longer fast pathway refractory period than those who were younger [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/27\">",
"     27",
"    </a>",
"    ]. There was no difference in either in the frequency of syncope or atrial fibrillation and radiofrequency ablation was equally effective in the two groups. Another comparison of patients older and younger than 65 years of age also found that the older group had more heart disease, the A-H and H-V intervals and the slow pathway refractory periods were longer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ELECTROCARDIOGRAPHIC CHARACTERISTICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     General features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual electrocardiographic features of AVNRT include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate is generally between 120 and 220",
"      <span class=\"nowrap\">",
"       beats/minute.",
"      </span>",
"     </li>",
"     <li>",
"      In the common form (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Common form of the arrhythmia'",
"      </a>",
"      above), retrograde atrial activation and antegrade ventricular activation occur almost simultaneously (",
"      <a class=\"graphic graphic_figure graphicRef50122 \" href=\"UTD.htm?42/30/43501\">",
"       figure 3",
"      </a>",
"      ). The P wave, therefore, is usually buried within or fused with the QRS complex. A component of the P wave is often evident slightly after, or less commonly before, the QRS (",
"      <a class=\"graphic graphic_figure graphicRef54290 \" href=\"UTD.htm?32/3/32830\">",
"       figure 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef57001 \" href=\"UTD.htm?38/58/39850\">",
"       waveform 3",
"      </a>",
"      ). When the P wave occurs shortly after the QRS complex, the fused waveform can produce a pseudo-R' (a second R wave) in lead V1 and a pseudo-S wave in the inferior leads.",
"     </li>",
"     <li>",
"      If the initiation of the tachycardia is captured on a tracing, the tachycardia often begins with a premature atrial depolarization with sudden prolongation of the PR interval (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Common form of the arrhythmia'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      In the uncommon form of AVNRT (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Uncommon forms'",
"      </a>",
"      above), retrograde atrial activation occurs long after ventricular activation, resulting in a P wave so late after the QRS complex that it appears to be occurring shortly before the next QRS complex (",
"      <a class=\"graphic graphic_figure graphicRef56806 \" href=\"UTD.htm?22/16/22799\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef66828 \" href=\"UTD.htm?31/31/32240\">",
"       figure 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef81639 \" href=\"UTD.htm?38/48/39690\">",
"       waveform 2",
"      </a>",
"      ). This pattern resembles that seen in atrial tachycardias. In such cases, an EP study may be required to define the arrhythmogenic mechanism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the relationships between the QRS complex and the following P wave, the common form of AVNRT is referred to as a \"short RP tachycardia\", while the uncommon form is a \"long RP tachycardia\" [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'RP relationship'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     P wave morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The axis of the P wave, when seen, is abnormal due to retrograde atrial activation. This is usually manifested on the electrocardiogram by inverted P waves in leads I, II, III and aVF. In atypical AVNRT, however, the P wave is generally upright or isoelectric in lead I [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     ST segment depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant ST segment depression during tachycardia has been observed in 25 to 50 percent of patients with AVNRT, although it is more commonly seen in those with an AV reentrant tachycardia associated with an accessory pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Although the presence of ST segment depression suggests myocardial ischemia, the majority of patients do not have underlying coronary artery disease; in these patients ST segment changes represent either repolarization changes or a retrograde atrial activation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     T wave inversions after termination",
"    </span>",
"    &nbsp;&mdash;&nbsp;After acute termination of AVNRT and other paroxysmal SVTs, T wave inversions may be seen in the anterior or inferior leads. In a series of 63 patients with paroxysmal SVT, such abnormalities were present in about 40 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/34\">",
"     34",
"    </a>",
"    ]. They may be seen immediately upon AVNRT termination or may develop within the first six hours, and can persist for a variable duration (mean of 34 hours). The occurrence of negative T waves is not predicted by clinical parameters, tachycardia rate or duration, or the presence and extent of ST segment depression during the tachycardia. They are not the result of coronary artery disease, but are repolarization abnormalities, likely due to ionic current alterations resulting from the rapid rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general approach to the therapy of AVNRT includes two components, acute termination of the arrhythmia and prevention of recurrent episodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Acute termination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended approach to acute termination of AVNRT depends upon the severity of the arrhythmia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Hemodynamic collapse or severe symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe hemodynamic decompensation is uncommon in AVNRT. Hemodynamic compromise may be manifested clinically by one or more of the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypotension and shock",
"     </li>",
"     <li>",
"      Angina pectoris",
"     </li>",
"     <li>",
"      Shortness of breath",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      heart failure",
"     </li>",
"     <li>",
"      Syncope or near-syncope",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In such cases, immediate restoration of normal sinus rhythm is essential. Based upon their speed of onset and high therapeutic efficacy, treatment options in this setting include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"       Adenosine",
"      </a>",
"     </li>",
"     <li>",
"      DC cardioversion (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=see_link&amp;anchor=H15#H15\">",
"       \"Cardioversion for specific arrhythmias\", section on 'Supraventricular tachycardia'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Stable patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data regarding the optimal approach to the acute termination of AVNRT. Management recommendations are based upon an understanding of the properties and risks of the treatment options. In 2003, the American College of Cardiology (ACC), the American Heart Association (AHA), and the European Society of Cardiology (ESC) published guidelines for the management of patients with supraventricular arrhythmias, which included recommendations on the acute treatment of AVNRT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/35\">",
"     35",
"    </a>",
"    ]. Our recommendations are in general agreement with those guidelines.",
"   </p>",
"   <p>",
"    In patients who are hemodynamically stable, whether symptomatic or asymptomatic, we suggest the following approach to acute termination of the arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/36-40\">",
"     36-40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vagal maneuvers (eg, Valsalva maneuver or carotid sinus massage) &mdash; Vagal maneuvers increase parasympathetic tone, which produces a gradual slowing of conduction in the antegrade slow pathway. Slowing and eventual block in the antegrade slow pathway are the usual cause for arrhythmia termination with these interventions [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/24\">",
"       24",
"      </a>",
"      ], although they can also produce abrupt block in the retrograde fast pathway. Vagal maneuvers are less effective in hemodynamically unstable patients, since this state is typically characterized by increased sympathetic tone and parasympathetic withdrawal. A detailed discussion of the use of vagal maneuvers is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/46/21224?source=see_link\">",
"       \"Vagal maneuvers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"       Adenosine",
"      </a>",
"      &mdash; If vagal maneuvers cannot be performed or if they fail to terminate the arrhythmia, adenosine is usually the first pharmacologic agent administered. The advantages of adenosine over other agents include rapid onset and a short half-life. Adenosine terminates AVNRT in over 80 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/36-38\">",
"       36-38",
"      </a>",
"      ]. It is well tolerated in most patients, with the exception of those with severe bronchospastic asthma or severe coronary artery disease. Detailed discussions of the use of adenosine for the evaluation and termination of SVTs are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'Intravenous adenosine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nondihydropyridine calcium channel blockers &mdash; If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"       adenosine",
"      </a>",
"      is ineffective, intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      can be used to terminate AVNRT [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/39\">",
"       39",
"      </a>",
"      ]. These drugs are generally well-tolerated, although potential adverse effects include hypotension (due to both negative inotropic and vasodilatory effects) and bradycardia [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/41-43\">",
"       41-43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Beta blockers &mdash; Intravenous beta blockers (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"       esmolol",
"      </a>",
"      ), are alternatives to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      in patients who do not respond to or are intolerant of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"       adenosine",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/40\">",
"       40",
"      </a>",
"      ]. Similar to the calcium channel blockers, beta blockers have the potential to cause hypotension",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bradycardia, and therefore they should be used cautiously, particularly if calcium channel blockers have already been administered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of their longer half-lives,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , and beta blockers have the potential to suppress arrhythmia recurrence. Thus, these drugs should be used in patients who have early arrhythmia recurrence after termination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Pill-in-the-pocket",
"    </span>",
"    &nbsp;&mdash;&nbsp;In selected patients with infrequent, well-tolerated, and long lasting episodes of AVNRT, a single dose of an antiarrhythmic agent that was previously evaluated under observation can be effective for acute termination of the arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. This strategy can both reduce the need for emergency department visits and avoid chronic medical therapy or invasive procedures. This approach has been evaluated with the nondihydropyridine calcium channel blockers, beta blockers, and the class IC antiarrhythmic drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/45\">",
"     45",
"    </a>",
"    ]. However, based upon the efficacy of alternative, lower-risk therapies, flecainide is rarely used in the management of AVNRT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Chronic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all AVNRT patients require long-term suppressive therapy. The decision to treat is based upon the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The frequency of the arrhythmia",
"     </li>",
"     <li>",
"      The significance of the symptoms",
"     </li>",
"     <li>",
"      Patient tolerance of medications",
"     </li>",
"     <li>",
"      Patient preference",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with symptomatic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    frequent episodes of AVNRT are generally treated with either catheter ablation or chronic suppressive pharmacologic therapy. There are few data to guide the selection of a specific therapy, and choices are influenced by patient preference. The 2003",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines on the management of supraventricular arrhythmias included recommendations for the chronic therapy of AVNRT, and as with acute therapies, our recommendations are in general agreement with those guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     No treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with infrequent and well-tolerated episodes of AVNRT may choose no chronic therapy. Such patients can be taught to terminate the arrhythmia using safe vagotonic maneuvers, particularly the Valsalva maneuver and its variants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/46/21224?source=see_link\">",
"     \"Vagal maneuvers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data comparing the relative efficacy of various agents. Because they are effective and well tolerated, the medications that are most commonly used for the chronic suppression of AVNRT are the nondihydropyridine calcium channel blockers",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , and &szlig;-blockers.",
"   </p>",
"   <p>",
"    Among patients who do not respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    or &szlig;-blockers and who do not want to pursue EP study and ablation, the following antiarrhythmic drugs may be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       Flecainide",
"      </a>",
"      (class IC)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       Propafenone",
"      </a>",
"      (class IC)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       Sotalol",
"      </a>",
"      (class III)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      (class III)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, due to the potential for significant toxicities, including proarrhythmia, the use of class I and class III antiarrhythmic drugs for the management of AVNRT should be reserved for rare cases and should be administered in consultation with an electrophysiologist. In particular, because of the risk of toxicities with long-term use,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is usually avoided in young patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Catheter ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter ablation offers the opportunity for definitive control of the arrhythmia and the avoidance of chronic medical therapy. However, ablation incurs the risks of procedural complications, including a 1 percent risk of heart block requiring a pacemaker. Due to its favorable efficacy and safety profile, this option is increasingly favored among patients with recurrent AVNRT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=see_link\">",
"     \"Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Selecting an approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;AVNRT is usually well-tolerated, and a variety of treatment options are safe and effective. Thus, in the absence of compelling data favoring one therapy over another, the choice of chronic treatment strategies is influenced by patient preference. When working with a patient to select a treatment strategy, the following issues should be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many patients with well-tolerated symptoms prefer a more conservative initial approach, with either no specific therapy or pharmacologic suppression.",
"     </li>",
"     <li>",
"      If pharmacologic therapy fails or if the side effects of chronic medications are poorly tolerated, patients often prefer EP study and ablation [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24793/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For patients who prefer definitive therapy, even for rare, well-tolerated episodes, catheter ablation is a reasonable option.",
"     </li>",
"     <li>",
"      For patients with episodes of AVNRT that are poorly tolerated (eg, associated with near-syncope or syncope, angina, or severe dyspnea), we suggest catheter ablation as initial therapy. In such cases, the risks associated with recurrent arrhythmic events (eg, syncope with associated trauma) outweigh the procedural risks. In addition, the potential for definitive therapy makes ablation preferable to medical therapy in this setting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/45/11986?source=see_link\">",
"       \"Patient information: Supraventricular tachycardia (SVT) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following summary and recommendations apply to the clinical features and general management of AVNRT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AVNRT is categorized as one of the paroxysmal SVTs, and is the most common of these arrhythmias, accounting for nearly two-thirds of cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'Paroxysmal SVT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptom onset usually occurs in young adulthood. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most widely accepted pathophysiologic model for AVNRT involves dual AV nodal pathways, which create the substrate for a reentrant arrhythmia. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Dual AV nodal physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both common and uncommon forms of the arrhythmia occur. These forms are distinguished by which of the dual (or multiple) AV nodal pathways are used as the antegrade and retrograde limbs of the reentrant circuit. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Common form of the arrhythmia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Uncommon forms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Characteristic P wave timing and morphology help to distinguish AVNRT from other SVTs. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Electrocardiographic characteristics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Arrhythmia termination",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with AVNRT associated with severe symptoms due to the tachycardia (eg, angina, hypotension, or heart failure) require rapid termination of the arrhythmia. If intravenous access is available, we suggest an initial attempt at termination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"       adenosine",
"      </a>",
"      rather than cardioversion (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If adenosine cannot be administered or is ineffective, patients should undergo immediate DC cardioversion. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Hemodynamic collapse or severe symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with AVNRT that is associated with hemodynamic collapse, we recommend immediate DC cardioversion (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Hemodynamic collapse or severe symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with AVNRT that is not associated with severe symptoms or hemodynamic collapse, including patients without symptoms, we suggest the following approach to acute termination (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Stable patient'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Vagal maneuvers",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"       Adenosine",
"      </a>",
"     </li>",
"     <li>",
"      Nondihydropyridine calcium channel blocker or a beta blocker",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Chronic suppression",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have experienced one or more episodes of poorly tolerated AVNRT, we suggest catheter ablation as opposed to chronic suppressive medical therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Selecting an approach'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=see_link\">",
"       \"Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with recurrent episodes of AVNRT that are well tolerated, the choice of therapy is based upon patient preference. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Selecting an approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2032434873\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to thank Dr. David Wilber, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/1\">",
"      Hayes JJ, Sharma PP, Smith PN, Vidaillet HJ. Familial atrioventricular nodal reentry tachycardia. Pacing Clin Electrophysiol 2004; 27:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/2\">",
"      Abe H, Nagatomo T, Kobayashi H, et al. Neurohumoral and hemodynamic mechanisms of diuresis during atrioventricular nodal reentrant tachycardia. Pacing Clin Electrophysiol 1997; 20:2783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/3\">",
"      Wood KA, Drew BJ, Scheinman MM. Frequency of disabling symptoms in supraventricular tachycardia. Am J Cardiol 1997; 79:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/4\">",
"      Doi A, Miyamoto K, Uno K, et al. Studies on hemodynamic instability in paroxysmal supraventricular tachycardia: noninvasive evaluations by head-up tilt testing and power spectrum analysis on electrocardiographic RR variation. Pacing Clin Electrophysiol 2000; 23:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/5\">",
"      Leitch JW, Klein GJ, Yee R, et al. Syncope associated with supraventricular tachycardia. An expression of tachycardia rate or vasomotor response? Circulation 1992; 85:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/6\">",
"      Wang YS, Scheinman MM, Chien WW, et al. Patients with supraventricular tachycardia presenting with aborted sudden death: incidence, mechanism and long-term follow-up. J Am Coll Cardiol 1991; 18:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/7\">",
"      Goyal R, Zivin A, Souza J, et al. Comparison of the ages of tachycardia onset in patients with atrioventricular nodal reentrant tachycardia and accessory pathway-mediated tachycardia. Am Heart J 1996; 132:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/8\">",
"      Chen SA, Chiang CE, Tai CT, et al. Longitudinal clinical and electrophysiological assessment of patients with symptomatic Wolff-Parkinson-White syndrome and atrioventricular node reentrant tachycardia. Circulation 1996; 93:2023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/9\">",
"      McGuire MA, Bourke JP, Robotin MC, et al. High resolution mapping of Koch's triangle using sixty electrodes in humans with atrioventricular junctional (AV nodal) reentrant tachycardia. Circulation 1993; 88:2315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/10\">",
"      McGuire MA, Janse MJ, Ross DL. \"AV nodal\" reentry: Part II: AV nodal, AV junctional, or atrionodal reentry? J Cardiovasc Electrophysiol 1993; 4:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/11\">",
"      Janse MJ, Anderson RH, McGuire MA, Ho SY. \"AV nodal\" reentry: Part I: \"AV nodal\" reentry revisited. J Cardiovasc Electrophysiol 1993; 4:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/12\">",
"      Pieper SJ, Stanton MS. Narrow QRS complex tachycardias. Mayo Clin Proc 1995; 70:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/13\">",
"      Mazgalev TN, Tchou PJ. Surface potentials from the region of the atrioventricular node and their relation to dual pathway electrophysiology. Circulation 2000; 101:2110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/14\">",
"      MOE GK, PRESTON JB, BURLINGTON H. Physiologic evidence for a dual A-V transmission system. Circ Res 1956; 4:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/15\">",
"      Man KC, Brinkman K, Bogun F, et al. 2:1 atrioventricular block during atrioventricular node reentrant tachycardia. J Am Coll Cardiol 1996; 28:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/16\">",
"      Schmitt C, Miller JM, Josephson ME. Atrioventricular nodal supraventricular tachycardia with 2:1 block above the bundle of His. Pacing Clin Electrophysiol 1988; 11:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/17\">",
"      Yeh SJ, Yamamoto T, Lin FC, Wu D. Atrioventricular block in the atypical form of junctional reciprocating tachycardia: evidence supporting the atrioventricular node as the site of reentry. J Am Coll Cardiol 1990; 15:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/18\">",
"      Yamabe H, Shimasaki Y, Honda O, et al. Demonstration of the exact anatomic tachycardia circuit in the fast-slow form of atrioventricular nodal reentrant tachycardia. Circulation 2001; 104:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/19\">",
"      Bogun F, Daoud E, Goyal R, et al. Comparison of atrial-His intervals in patients with and without dual atrioventricular nodal physiology and atrioventricular nodal reentrant tachycardia. Am Heart J 1996; 132:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/20\">",
"      Wu J, Zipes DP. Mechanisms underlying atrioventricular nodal conduction and the reentrant circuit of atrioventricular nodal reentrant tachycardia using optical mapping. J Cardiovasc Electrophysiol 2002; 13:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/21\">",
"      Kwaku KF, Josephson ME. Typical AVNRT--an update on mechanisms and therapy. Card Electrophysiol Rev 2002; 6:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/22\">",
"      Otomo K, Suyama K, Okamura H, et al. Participation of a concealed atriohisian tract in the reentrant circuit of the slow-fast type of atrioventricular nodal reentrant tachycardia. Heart Rhythm 2007; 4:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/23\">",
"      Otomo K, Nagata Y, Uno K, et al. Atypical atrioventricular nodal reentrant tachycardia with eccentric coronary sinus activation: electrophysiological characteristics and essential effects of left-sided ablation inside the coronary sinus. Heart Rhythm 2007; 4:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/24\">",
"      Belz MK, Stambler BS, Wood MA, et al. Effects of enhanced parasympathetic tone on atrioventricular nodal conduction during atrioventricular nodal reentrant tachycardia. Am J Cardiol 1997; 80:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/25\">",
"      Chiou CW, Chen SA, Kung MH, et al. Effects of continuous enhanced vagal tone on dual atrioventricular node and accessory pathways. Circulation 2003; 107:2583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/26\">",
"      Liuba I, J&ouml;nsson A, S&auml;fstr&ouml;m K, Walfridsson H. Gender-related differences in patients with atrioventricular nodal reentry tachycardia. Am J Cardiol 2006; 97:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/27\">",
"      Meiltz A, Zimmermann M. Atrioventricular nodal reentrant tachycardia in the elderly: efficacy and safety of radiofrequency catheter ablation. Pacing Clin Electrophysiol 2007; 30 Suppl 1:S103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/28\">",
"      Grecu M, Floria M, Georgescu CA. Abnormal atrioventricular node conduction and atrioventricular nodal reentrant tachycardia in patients older versus younger than 65 years of age. Pacing Clin Electrophysiol 2009; 32 Suppl 1:S98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/29\">",
"      Ng KS, Lauer MR, Young C, et al. Correlation of P-wave polarity with underlying electrophysiologic mechanisms of long RP' tachycardia. Am J Cardiol 1996; 77:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/30\">",
"      Riva SI, Della Bella P, Fassini G, et al. Value of analysis of ST segment changes during tachycardia in determining type of narrow QRS complex tachycardia. J Am Coll Cardiol 1996; 27:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/31\">",
"      G&uuml;le&ccedil; S, Erta�� F, Karao��uz R, et al. Value of ST-segment depression during paroxysmal supraventricular tachycardia in the diagnosis of coronary artery disease. Am J Cardiol 1999; 83:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/32\">",
"      Imrie JR, Yee R, Klein GJ, Sharma AD. Incidence and clinical significance of ST segment depression in supraventricular tachycardia. Can J Cardiol 1990; 6:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/33\">",
"      Petsas AA, Anastassiades LC, Antonopoulos AG. Exercise testing for assessment of the significance of ST segment depression observed during episodes of paroxysmal supraventricular tachycardia. Eur Heart J 1990; 11:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/34\">",
"      Paparella N, Ouyang F, Fuc�� G, et al. Significance of newly acquired negative T waves after interruption of paroxysmal reentrant supraventricular tachycardia with narrow QRS complex. Am J Cardiol 2000; 85:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/35\">",
"      Blomstr&ouml;m-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation 2003; 108:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/36\">",
"      Glatter KA, Cheng J, Dorostkar P, et al. Electrophysiologic effects of adenosine in patients with supraventricular tachycardia. Circulation 1999; 99:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/37\">",
"      Cairns CB, Niemann JT. Intravenous adenosine in the emergency department management of paroxysmal supraventricular tachycardia. Ann Emerg Med 1991; 20:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/38\">",
"      Rankin AC, Brooks R, Ruskin JN, McGovern BA. Adenosine and the treatment of supraventricular tachycardia. Am J Med 1992; 92:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/39\">",
"      Waxman HL, Myerburg RJ, Appel R, Sung RJ. Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter: a double-blind randomized cross-over study. Ann Intern Med 1981; 94:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/40\">",
"      Das G, Tschida V, Gray R, et al. Efficacy of esmolol in the treatment and transfer of patients with supraventricular tachyarrhythmias to alternate oral antiarrhythmic agents. J Clin Pharmacol 1988; 28:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/41\">",
"      Sung RJ, Elser B, McAllister RG Jr. Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations. Ann Intern Med 1980; 93:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/42\">",
"      DiMarco JP, Sellers TD, Berne RM, et al. Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia. Circulation 1983; 68:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/43\">",
"      Dougherty AH, Jackman WM, Naccarelli GV, et al. Acute conversion of paroxysmal supraventricular tachycardia with intravenous diltiazem. IV Diltiazem Study Group. Am J Cardiol 1992; 70:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/44\">",
"      Margolis B, DeSilva RA, Lown B. Episodic drug treatment in the management of paroxysmal arrhythmias. Am J Cardiol 1980; 45:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/45\">",
"      Alboni P, Tomasi C, Menozzi C, et al. Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. J Am Coll Cardiol 2001; 37:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24793/abstract/46\">",
"      Goldberg AS, Bathina MN, Mickelsen S, et al. Long-term outcomes on quality-of-life and health care costs in patients with supraventricular tachycardia (radiofrequency catheter ablation versus medical therapy). Am J Cardiol 2002; 89:1120.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 902 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-B6CE745EC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_13_24793=[""].join("\n");
var outline_f24_13_24793=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ELECTROPHYSIOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dual AV nodal physiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Dual pathways during normal sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Anatomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Model limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Common form of the arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Uncommon forms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Effect of enhanced vagal tone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Gender differences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Age differences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ELECTROCARDIOGRAPHIC CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      General features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      P wave morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ST segment depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      T wave inversions after termination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Acute termination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Hemodynamic collapse or severe symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Stable patient",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Pill-in-the-pocket",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Chronic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - No treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Catheter ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Selecting an approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Arrhythmia termination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Chronic suppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2032434873\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/902\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/902|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/35/1598\" title=\"figure 1\">",
"      Common slow fast AVNRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/17/12562\" title=\"figure 2\">",
"      Anatomy of Koch's triangle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/30/43501\" title=\"figure 3\">",
"      ECG generation in common AVNRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/16/22799\" title=\"figure 4\">",
"      Uncommon fast slow AVNRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/31/32240\" title=\"figure 5\">",
"      Atypical atrioventricular nodal reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/3/32830\" title=\"figure 6\">",
"      Typical atrioventricular nodal reentrant tahcycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/902|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/56/7052\" title=\"table 1\">",
"      Electrophysiology in SVTach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/902|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?5/34/5672\" title=\"waveform 1A\">",
"      EPS tracing AVNRT dual AVN pathways I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?6/2/6184\" title=\"waveform 1B\">",
"      EPS tracing AVNRT dual AVN pathways II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?38/48/39690\" title=\"waveform 2\">",
"      12 lead ECG uncommon AVNRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?38/58/39850\" title=\"waveform 3\">",
"      12 lead ECG common AVNRT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=related_link\">",
"      Cardioversion for specific arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=related_link\">",
"      Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3097?source=related_link\">",
"      Invasive cardiac electrophysiology studies: Tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/45/11986?source=related_link\">",
"      Patient information: Supraventricular tachycardia (SVT) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/46/21224?source=related_link\">",
"      Vagal maneuvers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_13_24794="Clinical presentation and diagnosis of von Willebrand disease";
var content_f24_13_24794=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation and diagnosis of von Willebrand disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/13/24794/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/13/24794/contributors\">",
"     Margaret E Rick, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/13/24794/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/13/24794/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/13/24794/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/13/24794/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/13/24794/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Von Willebrand disease (VWD) is the most common inherited bleeding disorder, affecting up to 1 percent of the population as assessed by random laboratory screening, although only approximately 1 percent of these individuals are appreciably symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/1\">",
"     1",
"    </a>",
"    ]. It is characterized by mutations that lead to a decrease in the level or impairment in the action of von Willebrand factor (VWF) (",
"    <a class=\"graphic graphic_table graphicRef71525 \" href=\"UTD.htm?5/14/5356\">",
"     table 1",
"    </a>",
"    ). Most cases are transmitted as an autosomal dominant trait that affects males and females equally [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/2\">",
"     2",
"    </a>",
"    ]. There are also acquired forms of VWD that are caused by several different pathophysiologic mechanisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link\">",
"     \"Classification and pathophysiology of von Willebrand disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17049?source=see_link\">",
"     \"Biology and normal function of von Willebrand factor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical presentation and diagnosis of VWD will be reviewed here. Treatment of VWD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=see_link\">",
"     \"Treatment of von Willebrand disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMPORTANCE OF VON WILLEBRAND FACTOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Von Willebrand factor (VWF) plays an important role in primary hemostasis by binding to both platelets and endothelial components, forming an adhesive bridge between platelets and vascular subendothelial structures at sites of endothelial injury (",
"    <a class=\"graphic graphic_figure graphicRef81908 \" href=\"UTD.htm?7/17/7446\">",
"     figure 1",
"    </a>",
"    ) and between adjacent platelets in areas with high shear [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. It also contributes to fibrin clot formation by acting as a carrier protein for factor VIII, which has a greatly shortened half-life and abnormally low concentration unless it is bound to VWF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Von Willebrand factor circulates as a series of multimers formed from a basic dimer subunit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17049?source=see_link\">",
"     \"Biology and normal function of von Willebrand factor\"",
"    </a>",
"    .) High molecular weight VWF multimers are the most active form of VWF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], providing multiple binding sites that can interact with both platelet receptors and subendothelial structures at sites of injury. Plasma VWF is synthesized by megakaryocytes and endothelial cells and undergoes extensive post-synthetic processing. When released acutely from these cells, VWF contains even larger multimers than are normally observed in the circulation. These \"unusually large\" forms are prothrombotic [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/6\">",
"     6",
"    </a>",
"    ]; they are rapidly proteolyzed by the VWF cleaving protease (ADAMTS13) to the \"normal\" multimer size distribution as defined by a normal plasma pool [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17049?source=see_link\">",
"     \"Biology and normal function of von Willebrand factor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although decreased levels of VWF are relatively common, only a fraction of patients come to medical attention because of bleeding symptoms and are diagnosed as having VWD. This low incidence of bleeding is due to the mild nature of the disease in many patients and to the lack of bleeding challenges",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lack of recognition of minor excessive bleeding (eg, heavy menstrual bleeding) in others.",
"   </p>",
"   <p>",
"    Bleeding symptoms in VWD occur when von Willebrand factor (VWF) is sufficiently decreased in the plasma or when a qualitative defect in VWF impairs one of its functions. These abnormalities mostly affect platelet plug formation during the primary hemostatic response. As a result, many of the usual clinical manifestations of VWD are similar to those seen in platelet disorders. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Easy bruising",
"     </li>",
"     <li>",
"      Skin bleeding",
"     </li>",
"     <li>",
"      Prolonged bleeding from mucosal surfaces (eg, oropharyngeal, gastrointestinal, uterine).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An exception to this general pattern of bleeding occurs in type 2N VWD in which there is a qualitative defect in VWF that affects its binding site for factor VIII (see",
"    <a class=\"local\" href=\"#H27\">",
"     'Type 2N'",
"    </a>",
"    below). In these patients, the bleeding is due to low factor VIII levels and mimics the findings seen in classical hemophilia, including soft tissue, joint, and urinary bleeding, and bleeding after invasive procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. In patients with type 3 VWD, both types of bleeding (ie, mucocutaneous and soft tissue bleeding as well as joint bleeding) may occur (see",
"    <a class=\"local\" href=\"#H28\">",
"     'Type 3'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Patients with VWD can become symptomatic at any age. A typical history in a patient with mild to moderate disease includes epistaxis lasting longer than 10 minutes in childhood, lifelong easy bruising, and bleeding with or following dental extractions, other invasive dental procedures, or other forms of surgery.",
"   </p>",
"   <p>",
"    Women with VWD usually have a history of heavy menstrual bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/11\">",
"     11",
"    </a>",
"    ], and may have bleeding during the peripartum period, often at or within hours of delivery and at 5 to 10 days after delivery. The bleeding may be delayed until 14 to 21 days post-partum, or persist for this time period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=see_link\">",
"     \"Terminology and evaluation of abnormal uterine bleeding in premenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bleeding from the gastrointestinal tract can be serious, but is less common. Patients may have undergone surgical procedures without excessive bleeding if the surgeon has been meticulous with hemostasis during the procedure.",
"   </p>",
"   <p>",
"    In patients with mild VWD, the ingestion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or other antiplatelet medications such as nonsteroidal antiinflammatory drugs can precipitate bleeding that may not have occurred otherwise. Some patients remain asymptomatic, with the diagnosis being made during the course of screening studies because of a family member with newly-diagnosed severe VWD.",
"   </p>",
"   <p>",
"    Bleeding manifestations are more serious and tend to occur earlier in life in patients who have a VWD variant (type 2) or who are homozygous or doubly heterozygous for mutations in VWF (type 3 VWD). Type 3 patients often have symptoms in infancy (eg, with circumcision) or when they begin to be mobile, as bleeding occurs after the usual minor traumas associated with learning to crawl and walk.",
"   </p>",
"   <p>",
"    As noted above, soft tissue, joint, and urinary bleeding due to factor VIII deficiency can occur when there is a marked reduction in binding of factor VIII to VWF. This occurs in type 2N VWD which has a defect in factor VIII binding, or in type 3 in which there are factor VIII levels of less than 10 percent along with extremely low or absent plasma VWF. Eruption of deciduous teeth may also cause bleeding, and affected young women may have life-threatening hemorrhage when they reach menarche. Serious and often recurrent and intractable gastrointestinal bleeding also can occur, especially when associated with angiodysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8410?source=see_link\">",
"     \"Angiodysplasia of the gastrointestinal tract\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11160?source=see_link&amp;anchor=H11#H11\">",
"     \"Differential diagnosis and approach to the adolescent with abnormal uterine bleeding\", section on 'Bleeding disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;VWD should be considered in patients who present with the above clinical manifestations. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical presentation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"     \"Approach to the adult patient with a bleeding diathesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Personal and family history and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's personal and family history of bleeding episodes is important, and one needs to specifically seek a history of challenges such as invasive dental procedures, tonsillectomy, other surgical procedures (particularly involving mucous membrane surfaces), and menstrual and peripartum bleeding. In general, having several bleeding symptoms makes it more likely that the patient has VWD, and having a relative with a confirmed diagnosis of VWD also makes this diagnosis more likely [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A medication history is also important because of the frequent use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and non-steroidal anti-inflammatory drugs in the population.",
"   </p>",
"   <p>",
"    A scoring system has been designed that relates the usefulness of a bleeding history for the diagnosis of VWD and relates bleeding symptoms to the levels of VWF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. This tool has been validated in type 1 VWD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/20\">",
"     20",
"    </a>",
"    ], and, using information from the patient's level of VWF and the number of first-degree family members with reduced VWF levels, may provide minimal criteria for the diagnosis of type 1 VWD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/21\">",
"     21",
"    </a>",
"    ]. A condensed MCMDM-1VWD bleeding questionnaire, which correlates well with the full version, is also available [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms limited to bruising need to be interpreted with caution, particularly in women. Hematoma formation with bruising lends more significance to this symptom. A negative bleeding history does not rule out the diagnosis of VWD in patients with a family history of VWD.",
"   </p>",
"   <p>",
"    Physical examination should include a search for ecchymoses and hematomas, their size and location, and evidence for current or recent mucosal bleeding. A negative physical examination is not uncommon in patients with VWD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Screening of family members",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether or not to screen for VWD in an asymptomatic patient with a negative bleeding history but a positive family history is not entirely clear, especially if the patient has not yet been hemostatically challenged (ie, no prior surgery or significant trauma). The following issues are important in making this decision:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of VWD in the family should be a firm one with available data. Specifically, one would want to know how low their VWF values are and how much and what types of bleeding other family members have had.",
"     </li>",
"     <li>",
"      If the patient has not yet been challenged hemostatically, the decision to screen may depend on the patient's personal activities. If",
"      <span class=\"nowrap\">",
"       he/she",
"      </span>",
"      is quite active physically or plans to be, it may be reasonable to do the testing. If not, one might wait until the patient faces a challenge, although if the patient or family are anxious about this issue and want testing, one might be more likely to test earlier.",
"     </li>",
"     <li>",
"      If the patient's screening aPTT is totally normal in the face of no prior bleeding, additional testing is probably not indicated, unless the family history indicates that affected family members have unexpectedly low VWF values in the face of normal aPTTs, a rare occurrence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LABORATORY TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three tests are recommended as",
"    <strong>",
"     initial",
"    </strong>",
"    <strong>",
"     screening tests",
"    </strong>",
"    for VWD by the National Heart, Lung, and Blood Institute (see table for definitions) (",
"    <a class=\"graphic graphic_table graphicRef73391 \" href=\"UTD.htm?16/63/17404\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Plasma VWF antigen (VWF:Ag)",
"     </li>",
"     <li>",
"      Plasma VWF activity (ristocetin cofactor activity, VWF:RCo and VWF collagen binding, VWF:CB)",
"     </li>",
"     <li>",
"      Factor VIII activity (FVIII)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A VWF activity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antigen level of 30 international",
"    <span class=\"nowrap\">",
"     units/dL",
"    </span>",
"    or less is recommended to establish a firm diagnosis of VWD (see",
"    <a class=\"local\" href=\"#H623769\">",
"     'Low VWF versus type 1 VWD'",
"    </a>",
"    below). If there is still a high index of suspicion for VWD in the face of normal or equivocal initial results, further testing is carried out which first includes repeating the initial tests. If the repeat VWF levels are normal, other causes of bleeding should be investigated.",
"   </p>",
"   <p>",
"    If one of the VWF tests is abnormal, the following",
"    <strong>",
"     specialized assays",
"    </strong>",
"    should be performed (see table for definitions) (",
"    <a class=\"graphic graphic_table graphicRef73391 \" href=\"UTD.htm?16/63/17404\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      VWF multimer distribution using gel electrophoresis",
"     </li>",
"     <li>",
"      Ristocetin-induced platelet aggregation (RIPA)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These latter two tests should be performed to determine the type of VWD when initial tests are positive, since the type of VWD directs the choice of treatment.",
"   </p>",
"   <p>",
"    Ristocetin cofactor activity and VWF antigen tests can be performed on platelet VWF as well as plasma VWF, after VWF has been isolated from circulating platelets. However, methods and reference ranges are not well established for platelet-associated VWF. Decreased platelet VWF has been described as the sole cause of a bleeding diathesis in a few families whose plasma VWF is within the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     VWF antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma VWF antigen (VWF:Ag) was initially measured in an electroimmunoassay (Laurell method) using monospecific antibodies to VWF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/26\">",
"     26",
"    </a>",
"    ]. At present, this test is usually performed by enzyme-linked immunosorbent assay (ELISA) on microtiter plates [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Automated methods (utilizing latex beads coated with antibodies to VWF and patient plasma as the source of VWF) have also been introduced; they utilize a turbidimetric end-point. Results of the latex bead assay compare favorably with the ELISA in most, but not all, instances. A potential problem is that rheumatoid factors can falsely elevate the VWF latex assay [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     VWF activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;VWF activity is commonly assayed as ristocetin cofactor activity (VWF:RCo), which tests the ability of VWF to agglutinate platelets by binding to its primary receptor, platelet glycoprotein Ib (GP Ib) in the presence of ristocetin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17049?source=see_link\">",
"     \"Biology and normal function of von Willebrand factor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ristocetin is an antibiotic that was taken off the market because it caused thrombocytopenia in individuals with normal VWF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/31\">",
"     31",
"    </a>",
"    ]. It binds to both VWF and platelet glycoprotein Ib [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], and causes agglutination of platelets that can be assessed either visually using a tilt-tube method or with the use of a platelet aggregometer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/30-34\">",
"     30-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Formalinized platelets or fragments of platelet membranes can be conveniently used in this test, eliminating the need for fresh washed platelets for each assay [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/34\">",
"     34",
"    </a>",
"    ]. If fresh washed platelets are used, they will be activated by the binding of VWF to GP Ib, and will undergo a release reaction and a secondary aggregation reaction in response to the initial binding and agglutination. Ristocetin cofactor testing has been automated for a number of different analyzers.",
"   </p>",
"   <p>",
"    In practice, a standard curve for the ristocetin cofactor test is constructed by adding serial dilutions of a standard plasma preparation (the source of VWF) to fresh or formalinized washed platelets and then adding ristocetin to a final concentration of 1.0 to 1.2",
"    <span class=\"nowrap\">",
"     mg/mL.",
"    </span>",
"    The time to platelet agglutination is measured and graphed against the concentration of VWF. Dilutions of patient plasma are substituted for the standard plasma and are assessed in a similar way. The standard plasma used for the initial curve should be related to the WHO standard, and the results reported in international",
"    <span class=\"nowrap\">",
"     units/dL",
"    </span>",
"    or international",
"    <span class=\"nowrap\">",
"     units/mL,",
"    </span>",
"    where 100 percent activity equals 100 international",
"    <span class=\"nowrap\">",
"     units/dL",
"    </span>",
"    or 1 international",
"    <span class=\"nowrap\">",
"     units/mL.",
"    </span>",
"   </p>",
"   <p>",
"    The ristocetin cofactor test has been difficult to standardize from laboratory to laboratory, but it remains the \"gold standard\" for VWF activity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/24\">",
"     24",
"    </a>",
"    ]. It has been automated using turbidometric methods. The larger VWF multimers (see below) appear to be most active in these assays. Patients with type 2 VWD who lack the high molecular weight multimers usually have decreased ristocetin cofactor activity when compared with the VWF antigen levels [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other methods utilizing the ability of the patient's VWF to bind to glycoprotein Ib (GP Ib), or using specific antibodies that recognize the binding site on VWF for platelet GP Ib are being developed; these methods use an ELISA format or flow cytometry end-point, and may be automated [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Collagen binding assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;Collagen binding has been introduced as a second type of functional assay for VWF (VWF:CB), but is not widely used in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. The binding of plasma VWF to collagen-coated plates is dependent upon the quantity of VWF in plasma and on the presence of higher molecular weight multimers that bind more readily to collagen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/40,42,43\">",
"     40,42,43",
"    </a>",
"    ]. This functional assay takes longer to perform, but has gained acceptance in some clinical laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. It measures a different function of VWF from the Ristocetin cofactor activity. Three distinct mutations have been described in families with VWD that cause defective collagen binding and bleeding without other VWF functional defects [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H623617\">",
"    <span class=\"h2\">",
"     Factor VIII activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since normal VWF protects factor VIII from proteolysis, decreased plasma VWF or a mutation in the VWF binding site for factor VIII (eg, type 2N VWD) can lead to decreased plasma factor VIII concentrations. If factor VIII is sufficiently decreased, it causes a prolonged activated partial thromboplastin time (aPTT) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/5\">",
"     5",
"    </a>",
"    ]. Although factor VIII activity is generally assessed in a one-stage functional assay using a fibrin clot as the end-point (modified aPTT assay), it may also be measured in a chromogenic assay that is not widely used [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factor VIII activity is usually slightly higher than VWF activity in VWD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/48\">",
"     48",
"    </a>",
"    ], and factor VIII levels are often in the low normal range in mild cases of VWD. Exceptions include type 2N VWD, in which very low levels of factor VIII are found [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], and type 3, which has very low levels of both factor VIII and VWF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Ratio of VWF activity to VWF antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratories are making use of this ratio to detect patients with type 2 VWD, where there is non-functional VWF in the circulation. Since the qualitative defects present in type 2A, 2B, and 2M all decrease the functional activity of VWF more than the antigen concentration, a low ratio may be used to predict these type 2 patients. Typically, the VWF:RCo to VWF:Ag ratio (or the VWF:CB to VWF:Ag ratio) is used.",
"   </p>",
"   <p>",
"    Most laboratories, however, have not standardized this ratio in a large group of type 1 VWD patients or normal subjects, so the absolute cut-off for this ratio is not known. Type 1 VWD patients usually have a ratio greater than 0.7, with probable lower limits in the range of 0.5 to 0.7. An activity to antigen ratio of less than this should lead to a multimer gel evaluation and also to consideration of VWD type 2A, 2B, or 2M. The latter may be particularly difficult to discriminate from type 1 VWD without the use of molecular studies.",
"   </p>",
"   <p>",
"    Racial differences in this ratio have been noted, due to an increased frequency of the D1472H VWF polymorphism in African Americans, which leads to slightly lower VWF:RCo levels [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/49\">",
"     49",
"    </a>",
"    ]. This is a limitation of the current &ldquo;functional&rdquo; assay using ristocetin and may result in some otherwise normal subjects or VWD patients being erroneously classified as having VWD type 2M.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Diagnosis of VWD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to make the diagnosis of VWD, one must take into account:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The patient's personal and family history of bleeding",
"     </li>",
"     <li>",
"      The laboratory assessment that includes the initial three tests listed above; laboratory evaluation is critical for the diagnosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnostic levels for VWF:Ag, VWF:RCo and factor VIII recommended by the NHLBI Working Group are indicated in the table (",
"    <a class=\"graphic graphic_table graphicRef75092 \" href=\"UTD.htm?11/36/11851\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Other screening assays that are sometimes utilized are noted below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Platelet function analyzer assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another functional assay, one that assesses the VWF-platelet interaction and measures platelet plug formation in citrated whole blood, utilizes a platelet function analyzer, the PFA 100 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/50\">",
"     50",
"    </a>",
"    ]. The sample is aspirated through a capillary tube to a collagen + epinephrine or a collagen + adenosine diphosphate-coated membrane that contains a central aperture. The time to closure of the aperture by the forming platelet plug is measured. The closure time is dependent upon both VWF and intrinsic platelet function.",
"   </p>",
"   <p>",
"    This instrument has been used as a screening test for VWD, with high sensitivity, specificity, and negative predictive value [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. It has been debated, however, whether it should be used as a screening tool for VWD, and this test is not included in the recommended diagnostic assays by the NHLBI guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=see_link&amp;anchor=H17#H17\">",
"     \"Platelet function testing\", section on 'The platelet function analyzer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Bleeding time",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bleeding time (BT) is a measure of the interaction of platelets with the blood vessel wall. It is prolonged in patients with some intrinsic platelet disorders and in moderately severe and severe VWD, but is often normal in those with mild or moderate VWD. Although the BT does not correlate well with any specific plasma VWF assay [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/56\">",
"     56",
"    </a>",
"    ], it is helpful diagnostically if it is abnormal. It has been suggested that the levels of ristocetin cofactor and VWF:Ag in platelets correlate better with the BT than the plasma values of these tests [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, no study has shown a good correlation between the BT and bleeding symptoms in patients with VWD. Similarly, because the BT may be subject to considerable variation due to technical factors in executing the test, it is not recommended as a preoperative screening test to predict the likelihood of excessive bleeding during and after a procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link&amp;anchor=H13#H13\">",
"     \"Approach to the adult patient with a bleeding diathesis\", section on 'Bleeding time'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32439?source=see_link&amp;anchor=H7#H7\">",
"     \"Preoperative assessment of hemostasis\", section on 'Bleeding time'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When screening assays for VWD (ie, VWF:Ag, VWF:RCo, or factor VIII) are abnormal, further testing should be done to categorize the subtype of VWD that the patient has. These specialized tests include VWF multimer assessment and ristocetin induced platelet aggregation (RIPA), and are discussed below.",
"   </p>",
"   <p>",
"    Once the diagnosis of VWD is established, tests for classification of the type of VWD usually include two assays: VWF multimer and ristocetin-induced platelet aggregation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     VWF multimers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The VWF multimer assay is a qualitative visual assessment of the size spectrum and the banding pattern of VWF multimers that can be seen on gel electrophoresis of the patient's plasma or platelet VWF (",
"    <a class=\"graphic graphic_picture graphicRef71943 \" href=\"UTD.htm?15/1/15391\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/59\">",
"     59",
"    </a>",
"    ]. This test is used to identify variants of type 2 VWD that lack the largest multimers (types 2A and 2B), or have unusually large multimers, or other qualitatively abnormal \"bands\" that indicate an abnormal VWF structure (",
"    <a class=\"graphic graphic_table graphicRef71525 \" href=\"UTD.htm?5/14/5356\">",
"     table 1",
"    </a>",
"    ). The test consists of electrophoresis of plasma (or isolated platelet VWF) in low concentration agarose gels. The separated multimers may be transferred to a membrane and developed, or the gel may be developed directly using anti-VWF antibodies and chemiluminescence or autoradiography [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/4,60\">",
"     4,60",
"    </a>",
"    ]. Evaluation of the multimer distribution is done using visual assessment or densitometric scanning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Ristocetin induced platelet aggregation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ristocetin-induced platelet aggregation (RIPA) measures the affinity with which VWF binds to the platelet receptor GP Ib by limiting the concentration of ristocetin in the assay. It is used primarily to look for the type 2B variant of VWF which has mutations in the binding site for GP Ib such that the type 2B VWF binds to GP Ib more readily than normal (ie, a \"gain-of-function\" mutation, see below).",
"   </p>",
"   <p>",
"    Rather than using prepared formalinized or fresh washed platelets, RIPA uses the patient's fresh platelet-rich plasma (PRP) as a source of both VWF and platelets. The test is performed by placing the patient's PRP in a series of test tubes and sequentially adding lower concentrations of ristocetin to each tube, covering a range of concentrations from 0.4 to 1.2",
"    <span class=\"nowrap\">",
"     mg/mL.",
"    </span>",
"    The test's end-point is the presence or absence of platelet aggregation at each concentration of ristocetin. Platelet-rich plasma from patients with normal VWF does not respond (aggregate) to concentrations of ristocetin that are lower than approximately 0.6 to 0.8",
"    <span class=\"nowrap\">",
"     mg/mL,",
"    </span>",
"    but platelet-rich plasma from patients with type 2B VWD will aggregate at concentrations of ristocetin of 0.4 to 0.5",
"    <span class=\"nowrap\">",
"     mg/mL.",
"    </span>",
"   </p>",
"   <p>",
"    The RIPA assay assumes that the patient's GP Ib is qualitatively and quantitatively normal. In some cases, however, this assumption is not correct:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are rare \"gain-of-function\" mutations in platelet GP Ib that lead to increased binding of normal VWF, resulting in the same phenotype as type 2B VWD (",
"      <a class=\"graphic graphic_table graphicRef71525 \" href=\"UTD.htm?5/14/5356\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/61-63\">",
"       61-63",
"      </a>",
"      ]. This disorder is called platelet-type or pseudo VWD. A distinction between abnormal VWF and abnormal platelet receptors can be made by modifying the RIPA, using patient platelets and normal plasma VWF, or patient plasma VWF and normal platelets. A special Platelet Binding assay which measures the binding of patient's VWF to normal platelets in the presence of low concentrations of Ristocetin can also be used [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/64\">",
"       64",
"      </a>",
"      ]. Molecular studies of VWF and GP Ib further establish the specific defect.",
"     </li>",
"     <li>",
"      The Bernard-Soulier (BS) syndrome is a rare disorder in which there is a decrease or abnormality in platelet GP Ib that results in thrombocytopenia and giant platelets and greater than expected bleeding for the degree of thrombocytopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/65\">",
"       65",
"      </a>",
"      ]. Platelets from patients with BS do not aggregate in the presence of normal concentrations of VWF and ristocetin because of the decrease or abnormality in the GPIb.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624057\">",
"    <span class=\"h2\">",
"     Variations in VWF levels in health and disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a continuum of VWF levels between normal subjects and patients with VWD. Because plasma VWF levels can be increased for physiologic reasons, and because of the overlap of VWF levels between normal subjects and VWD patients, it is difficult to establish the diagnosis of mild VWD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/66\">",
"     66",
"    </a>",
"    ]. This difficulty is also compounded by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lack of correlation between bleeding symptoms and a specific level of VWF in an individual and by the frequent reporting of bleeding symptoms by normal subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of numerous ethnic-specific sequence variations in VWF, studied primarily in African Americans, many of which appear to be asymptomatic polymorphisms associated with normal levels of VWF [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with borderline results, it is often helpful to repeat the diagnostic testing at a second visit, making the environment as relaxed as possible; assessing family members who have a bleeding history can be helpful as well [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/68\">",
"     68",
"    </a>",
"    ]. The patient's blood type should also be determined, since normal individuals with type O blood have plasma levels of VWF that are 25 to 30 percent lower than those in type A, B, or AB individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Thus, in individuals with type O blood and moderate reductions in plasma VWF, the presence of a bleeding history and family studies may be needed to confirm or exclude a diagnosis of VWD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17049?source=see_link&amp;anchor=H5#H5\">",
"     \"Biology and normal function of von Willebrand factor\", section on 'Plasma VWF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of other physiologic or disease states can influence plasma VWF and factor VIII levels, and must be taken into account when trying to establish a diagnosis of inherited VWD. As an example, thyroid hormone and estrogen promote VWF synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Deficiency of thyroid hormone reduces plasma VWF in both normal subjects and patients with VWD. Conversely, patients with mild VWD who take birth control pills or estrogen replacement therapy may increase their slightly low VWF levels into the normal range, and during pregnancy VWF levels rise two- to fivefold [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to normal individual variability, plasma VWF and factor VIII are acute phase reactants, and their levels increase two to five times over baseline during exercise, adrenergic stimulation, and inflammatory processes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/74-79\">",
"     74-79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    .) As a result of the above variability, normal ranges for most of these factors are extremely broad, usually in the range of 50 to 200 international",
"    <span class=\"nowrap\">",
"     units/dL,",
"    </span>",
"    as compared with the activity found in normal pooled plasma, which is defined as 100 international",
"    <span class=\"nowrap\">",
"     units/dL.",
"    </span>",
"    A WHO standard exists for VWF, and reference plasmas or plasma pools should be referenced to this standard.",
"   </p>",
"   <p>",
"    Decisions about whether and when treatment such as DDAVP should be administered in patients with borderline VWF levels should be based on clinical criteria, including a history of bleeding and past challenges, the type of insult to the patient, and whether other factors predisposing to bleeding might be present, such as medications that might inhibit platelet function. In spite of the absence of a formal diagnosis in patients who have borderline values for VWF, they may be at risk for bleeding and may need treatment, such as DDAVP, before invasive procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIAGNOSIS (CLASSIFICATION) OF VWD TYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classification of VWD is based upon both clinical laboratory tests and genetic information about the mutations responsible for the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. VWD is divided into three major types (types 1, 2 [four subtypes], and 3) (",
"    <a class=\"graphic graphic_table graphicRef71525 \" href=\"UTD.htm?5/14/5356\">",
"     table 1",
"    </a>",
"    ). The genetic abnormalities and pathophysiology of these disorders are discussed in detail elsewhere. What follows is a brief review of the laboratory findings in each of the variants of inherited VWD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link\">",
"     \"Classification and pathophysiology of von Willebrand disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 1 VWD, an autosomal dominant disease, is the most common, accounting for approximately 75 percent of patients. The clinical presentation of type 1 VWD varies from mild to moderately severe as determined by bleeding symptoms, but some individuals are asymptomatic and detected incidentally in studies investigating a relative for VWD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link&amp;anchor=H6#H6\">",
"     \"Classification and pathophysiology of von Willebrand disease\", section on 'Clinical variability'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Type 1 VWD represents a partial quantitative deficiency of VWF; many of the mutations remain undefined. Several studies have identified various mutations in approximately two-thirds of patients with type 1 VWD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/80,81,83\">",
"     80,81,83",
"    </a>",
"    ], and other genetic loci that modify VWF synthesis or clearance may be important in the manifestation of this type of VWD.",
"   </p>",
"   <p>",
"    Rapid clearance of VWF can lead to low levels, and VWD Vicenza and several other cases of type 1 VWD are known to be caused by increased clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/82,84-86\">",
"     82,84-86",
"    </a>",
"    ]. Type 1 VWD patients with decreased VWF survival may be predicted by finding a rapid fall in the elevated VWF levels that result following DDAVP administration, and by finding an increased ratio of the VWF propeptide to VWF in the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/84\">",
"     84",
"    </a>",
"    ]. The VWF propeptide is synthesized as part of the VWF molecule and is cleaved before release of the mature VWF into the circulation. The normal ratio in the plasma of the VWF propeptide to VWF:Ag is 1:1.",
"   </p>",
"   <p>",
"    Laboratory testing in type 1 VWD usually reveals the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concordant reduction in VWF antigen, ristocetin cofactor activity, and factor VIII activity; factor VIII activity may be slightly higher than VWF levels",
"     </li>",
"     <li>",
"      All VWF multimers are present, although in decreased concentration",
"     </li>",
"     <li>",
"      RIPA is impaired only if VWF levels are sufficiently low (eg, moderately severe type 1 VWD).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Type 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2 VWD contains four subtypes, in which VWF is qualitatively abnormal, as demonstrated by VWF multimer patterns, RIPA, and an abnormally low VWF activity to antigen ratio (types 2A, 2B, and 2M), or by other special assays such as a quantitative assay of the patient's VWF binding for factor VIII (type 2N).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Type 2A",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2A accounts for approximately 10 to 15 percent of cases of VWD, and is usually transmitted as an autosomal dominant trait. Affected patients typically present with moderate to moderately severe bleeding.",
"   </p>",
"   <p>",
"    These patients have a decrease in the hemostatically active high and intermediate molecular weight multimers of VWF. Some mutations cause a defect in the intracellular assembly and transport of normal VWF multimers (group 1) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/87\">",
"     87",
"    </a>",
"    ], while others affect a normal cleavage site in VWF and cause increased susceptibility to proteolysis by the VWF-cleaving protease (ADAMTS13) after secretion (group 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory testing usually reveals the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ristocetin cofactor activity and VWF:Ag levels are often discordant, with ristocetin cofactor activity being lower than the antigen (ratio &lt;0.5 to 0.7) (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Ratio of VWF activity to VWF antigen'",
"      </a>",
"      above); the antigen may remain within the normal range.",
"     </li>",
"     <li>",
"      Factor VIII levels may be normal or reduced.",
"     </li>",
"     <li>",
"      VWF multimer gel patterns show an absence of the high and intermediate molecular weight multimers, as in lane 3 of the figure (",
"      <a class=\"graphic graphic_picture graphicRef71943 \" href=\"UTD.htm?15/1/15391\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      RIPA is reduced.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Type 2B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2B VWD accounts for approximately 5 percent of cases of VWD, and is transmitted as an autosomal dominant trait. Affected patients generally present with moderate or moderately severe bleeding. The abnormal VWF in this disorder has a \"gain of function\", binding more readily to the platelet receptor, glycoprotein Ib (",
"    <a class=\"graphic graphic_figure graphicRef60152 \" href=\"UTD.htm?33/37/34398\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/35\">",
"     35",
"    </a>",
"    ]. The increase in binding of larger multimers to platelet GP Ib results in their loss from the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/89\">",
"     89",
"    </a>",
"    ] and, in some patients, thrombocytopenia that is apparently due to clearance or sequestration of the small platelet aggregates that are formed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/35\">",
"     35",
"    </a>",
"    ]. A few type 2B patients have normal multimer patterns at baseline.",
"   </p>",
"   <p>",
"    Laboratory testing for type 2B VWD, which should always include low-dose ristocetin-induced platelet aggregation (RIPA), usually reveals the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VWF:Ag and ristocetin cofactor activity can be discordant, with the ristocetin cofactor activity being lower than the antigen.",
"     </li>",
"     <li>",
"      RIPA is \"increased\" (aggregation is present at low concentrations of ristocetin). The abnormal VWF binds to platelets at lower concentrations of ristocetin (&lt;0.6",
"      <span class=\"nowrap\">",
"       mg/mL)",
"      </span>",
"      than does normal VWF, causing the platelets to aggregate at low concentrations of ristocetin [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Factor VIII may be normal or decreased.",
"     </li>",
"     <li>",
"      The multimer pattern usually shows a decrease in the high molecular weight multimers, as in lane 4 of the figure (",
"      <a class=\"graphic graphic_picture graphicRef71943 \" href=\"UTD.htm?15/1/15391\">",
"       picture 1",
"      </a>",
"      ), often less severe than in type 2A VWD, as shown in lane 3 of the figure (",
"      <a class=\"graphic graphic_picture graphicRef71943 \" href=\"UTD.htm?15/1/15391\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Specialized assays that measure the direct binding of VWF to platelet GPIb in the presence of very low concentrations of ristocetin can also show the gain of function in type 2B VWD, but the assays require reagents that are not generally available to most laboratories [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/90,91\">",
"       90,91",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Platelet-type VWD",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phenotype similar to Type 2B can be produced by rare \"gain-of-function\" mutations in platelet GP Ib, called platelet-type or pseudo VWD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. A distinction between abnormal VWF and an abnormal platelet receptor can usually be made by mixing patient platelets with normal plasma VWF, and patient plasma VWF with normal platelets to perform the RIPA [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/92\">",
"     92",
"    </a>",
"    ]. The special Platelet Binding assay using low concentrations of ristocetin and gene mutation studies can also differentiate between type 2B and platelet-type VWD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Ristocetin induced platelet aggregation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Type 2M",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2M VWD is an uncommon, mostly autosomal dominant disorder characterized by reduced binding of VWF to GP Ib in spite of the presence of a normal distribution of VWF multimers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/93\">",
"     93",
"    </a>",
"    ]. Affected patients typically have significant bleeding symptoms and the following pattern on laboratory testing:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ristocetin cofactor is reduced more than VWF:Ag (ratio &lt;0.5 to 0.7).",
"     </li>",
"     <li>",
"      The full spectrum of VWF multimers is present.",
"     </li>",
"     <li>",
"      The factor VIII level is reduced if the VWF is sufficiently low.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The finding of the full spectrum of multimers differentiates type 2M from type 2A VWD. A decreased ratio of VWF:RCo to VWF:Ag helps distinguish type 2M from type 1. The multimer studies may also show an abnormal banding pattern in each individual multimer; variants that were previously classified as types IC and ID are examples [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. Variants with larger than normal multimers in plasma (\"Vicenza\" variant) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/96,97\">",
"     96,97",
"    </a>",
"    ] and variants that contain the propeptide in the multimers have been included in type 2M, although it may be more appropriate to classify these variants as type 1.",
"   </p>",
"   <p>",
"    The Bernard-Soulier syndrome is a rare disorder in which there is a decrease or abnormality in platelet GP Ib [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/65\">",
"     65",
"    </a>",
"    ]. It can be confused with type 1 or type 2M VWD if an abnormal RIPA is obtained without knowledge of the patient's ristocetin cofactor level. In patients with the Bernard-Soulier syndrome, the RIPA (requiring both normal platelet receptors and normal VWF in the test plasma) will be impaired, but the ristocetin cofactor activity is normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Type 2N",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2N VWD (N is for Normandy where one of the first patients was described) is an uncommon disorder that is inherited as an autosomal recessive trait. Patients present with the type of bleeding associated with factor VIII deficiency, such as soft tissue, joint, and urinary bleeding, and bleeding after invasive procedures (",
"    <a class=\"graphic graphic_table graphicRef71525 \" href=\"UTD.htm?5/14/5356\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It is characterized by mutations in VWF affecting the binding site for factor VIII (",
"    <a class=\"graphic graphic_figure graphicRef60152 \" href=\"UTD.htm?33/37/34398\">",
"     figure 2",
"    </a>",
"    ), leading to impaired binding and therefore rapid clearance of factor VIII [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/8-10,98-102\">",
"     8-10,98-102",
"    </a>",
"    ]. In order to be symptomatic, type 2N mutations must be inherited in a homozygous manner, or must occur in patients with a second VWF defect causing decreased synthesis of the second (normal) allele [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/9\">",
"     9",
"    </a>",
"    ]. Since the molar concentration in normal plasma of VWF monomers, each of which contains a factor VIII binding site, is much higher than that of factor VIII, the concentration of functional VWF molecules has to fall considerably below 50 percent in order to significantly reduce the factor VIII level [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A serious potential problem is that some patients with type 2N VWD are misdiagnosed as having hemophilia A. Type 2N VWD should be suspected in females who present with isolated factor VIII deficiency (with normal levels of VWF activity and antigen) and in families where an autosomal (rather than X-linked) inheritance pattern for factor VIII deficiency is suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory testing usually reveals the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ristocetin cofactor activity, VWF antigen, RIPA, and VWF multimer patterns are normal",
"     </li>",
"     <li>",
"      Levels of factor VIII are reduced, usually 5 to 15 percent of normal [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/10,99\">",
"       10,99",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A specialized test to assess binding of normal factor VIII to the patient's VWF demonstrates decreased binding [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/9,10\">",
"       9,10",
"      </a>",
"      ], and gene mutation studies will also reveal abnormalities in the VWF binding domain for factor VIII.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Type 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 3 VWD is a rare disease. Affected patients present with severe bleeding involving both the skin and mucous membrane surfaces (due to decreased VWF) and soft tissues and joints (due to the low concentration of factor VIII). In one large study from Iran involving 385 patients with type 3 VWD, hemarthrosis, muscle hematoma, oral cavity bleeding, and epistaxis were present in 37, 52, 70, and 77 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Type 3 VWD is characterized by a marked decrease or absence of detectable VWF due to homozygous or compound heterozygous mutations, some of which result in loss of VWF mRNA expression (",
"    <a class=\"graphic graphic_table graphicRef71525 \" href=\"UTD.htm?5/14/5356\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. Patients may be misdiagnosed initially as having hemophilia A before results of VWF testing are available.",
"   </p>",
"   <p>",
"    Laboratory testing usually reveals the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      VWF antigen is unmeasurable or extremely low",
"     </li>",
"     <li>",
"      Ristocetin cofactor activity is usually below the limits of detection",
"     </li>",
"     <li>",
"      Factor VIII activity is 1 to 10 percent of normal",
"     </li>",
"     <li>",
"      RIPA is absent",
"     </li>",
"     <li>",
"      VWF multimers are not usually visible on gel electrophoresis, as in lane 1 of the figure (",
"      <a class=\"graphic graphic_picture graphicRef71943 \" href=\"UTD.htm?15/1/15391\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H623769\">",
"    <span class=\"h2\">",
"     Low VWF versus type 1 VWD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for diagnostic limits to diagnose VWD have become more stringent, requiring levels of VWF activity and antigen of less than 30 international",
"    <span class=\"nowrap\">",
"     units/DL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef75092 \" href=\"UTD.htm?11/36/11851\">",
"     table 3",
"    </a>",
"    ), and individuals with mild bleeding symptoms and mildly decreased VWF levels are referred to as having \"low VWF\" rather than being labeled with a diagnosis of type 1 VWD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/107-111\">",
"     107-111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two observations inform this issue:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Very low levels of VWF (eg, 5 to 20 international",
"      <span class=\"nowrap\">",
"       units/dL)",
"      </span>",
"      tend to be highly heritable, are often associated with bleeding, and are frequently caused by apparently dominant VWF mutations. A diagnosis of type 1 VWD is justified for these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/107\">",
"       107",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      VWF levels of 35 to 50 international",
"      <span class=\"nowrap\">",
"       units/dL",
"      </span>",
"      show very low heritability, rarely segregate with bleeding symptoms, and rarely exhibit linkage to the VWF locus [",
"      <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/66,107-109\">",
"       66,107-109",
"      </a>",
"      ]. A diagnosis of \"low VWF\" may be more appropriate in these individuals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8873047\">",
"    <span class=\"h2\">",
"     Acquired VWD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acquired VWD (aVWD) should be suspected whenever laboratory findings suggest the presence of VWD, especially when aVWD-associated disorders are present (",
"    <a class=\"graphic graphic_table graphicRef54202 \" href=\"UTD.htm?16/62/17388\">",
"     table 4",
"    </a>",
"    ). Findings that favor aVWD over VWD include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?24/13/24794/abstract/112\">",
"     112",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Onset of bleeding later in life; history of prior uneventful surgery prior to bleeding episode(s)",
"     </li>",
"     <li>",
"      Negative family history for VWD",
"     </li>",
"     <li>",
"      Presence of an inhibitor to VWF or VWF-binding antibodies",
"     </li>",
"     <li>",
"      Remission of bleeding after treatment of an underlying aVWD-associated disorder",
"     </li>",
"     <li>",
"      Response to treatment with IVIG, suggesting IgG MGUS-associated aVWD",
"     </li>",
"     <li>",
"      Short-lived response to VWF-containing concentrates or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is especially important to rule out aVWD in patients with laboratory findings typical of VWD but without a positive family history. Routine history and physical examination, along with a complete blood count and serum protein electrophoresis, should be sufficient to detect most disorders associated with aVWD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/32/39425?source=see_link\">",
"       \"Patient information: von Willebrand disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/55/6002?source=see_link\">",
"       \"Patient information: von Willebrand disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H712828745\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H712828753\">",
"    <span class=\"h2\">",
"     When to suspect von Willebrand disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with von Willebrand disease (VWD) can become symptomatic at any age. The patient's personal and family history of bleeding episodes is important, and one needs to specifically seek a history of challenges such as invasive dental procedures, tonsillectomy, other surgical procedures (particularly involving mucous membrane surfaces), and menstrual and peripartum bleeding.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A typical history in a patient with mild to moderate disease includes epistaxis lasting longer than 10 minutes in childhood, lifelong easy bruising, and bleeding with or following dental extractions, other invasive dental procedures, or other forms of surgery. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnostic considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with type 2N VWD, the bleeding is due to low factor VIII levels and mimics the findings seen in classical hemophilia, including soft tissue, joint, and urinary bleeding, and bleeding after invasive procedures. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Type 2N'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with type 3 VWD, both types of bleeding (ie, mucocutaneous and soft tissue bleeding as well as joint bleeding) may occur (see",
"      <a class=\"local\" href=\"#H28\">",
"       'Type 3'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H712829008\">",
"    <span class=\"h2\">",
"     Initial testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three tests are recommended as initial screening tests for VWD (",
"    <a class=\"graphic graphic_table graphicRef73391 \" href=\"UTD.htm?16/63/17404\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Plasma VWF antigen (VWF:Ag)",
"     </li>",
"     <li>",
"      Plasma VWF activity (ristocetin cofactor activity, VWF:RCo and VWF collagen binding VWF:CB)",
"     </li>",
"     <li>",
"      Factor VIII activity (FVIII)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If there is still a high index of suspicion for VWD in the face of normal initial results, further testing is carried out which first includes",
"    <strong>",
"     repeating",
"    </strong>",
"    the initial tests. If the repeat VWF levels are normal, other causes of bleeding should be investigated. If one of the VWF tests is abnormal, the following specialized assays should be performed to determine the type of VWD (",
"    <a class=\"graphic graphic_table graphicRef73391 \" href=\"UTD.htm?16/63/17404\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      VWF multimer distribution using gel electrophoresis",
"     </li>",
"     <li>",
"      Ristocetin-induced platelet aggregation (RIPA)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H712829123\">",
"    <span class=\"h2\">",
"     Making a diagnosis of VWD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of VWD is made by assessing the results of initial testing; further tests delineate the type of VWD and help direct therapeutic choices. Representative results for the most common of the VWD types is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef71525 \" href=\"UTD.htm?5/14/5356\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/1\">",
"      Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/2\">",
"      Nilsson IM. Von Willebrand's disease--fifty years old. Acta Med Scand 1977; 201:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/3\">",
"      Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/4\">",
"      Ruggeri ZM, Ware J. von Willebrand factor. FASEB J 1993; 7:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/5\">",
"      Brinkhous KM, Sandberg H, Garris JB, et al. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci U S A 1985; 82:8752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/6\">",
"      Moake JL, Turner NA, Stathopoulos NA, et al. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986; 78:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/7\">",
"      Moake JL. von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Hematol 2004; 41:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/8\">",
"      Tuley EA, Gaucher C, Jorieux S, et al. Expression of von Willebrand factor \"Normandy\": an autosomal mutation that mimics hemophilia A. Proc Natl Acad Sci U S A 1991; 88:6377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/9\">",
"      Mazurier C, Dieval J, Jorieux S, et al. A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction. Blood 1990; 75:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/10\">",
"      Nishino M, Girma JP, Rothschild C, et al. New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989; 74:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/11\">",
"      Lukes AS, Kadir RA, Peyvandi F, Kouides PA. Disorders of hemostasis and excessive menstrual bleeding: prevalence and clinical impact. Fertil Steril 2005; 84:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/12\">",
"      Ahr DJ, Rickles FR, Hoyer LW, et al. von Willebrand's disease and hemorrhagic telangiectasia: association of two complex disorders of hemostasis resulting in life-threatening hemorrhage. Am J Med 1977; 62:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/13\">",
"      Bush RW, Huff JW. Von Willebrand's disease and severe gastrointestinal bleeding. Report of a kindred. West J Med 1984; 140:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/14\">",
"      Alhumood SA, Devine DV, Lawson L, et al. Idiopathic immune-mediated acquired von Willebrand's disease in a patient with angiodysplasia: demonstration of an unusual inhibitor causing a functional defect and rapid clearance of von Willebrand factor. Am J Hematol 1999; 60:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/15\">",
"      Sohal M, Laffan M. Von Willebrand disease and angiodysplasia responding to atorvastatin. Br J Haematol 2008; 142:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/16\">",
"      Hirri HM, Green PJ, Lindsay J. Von Willebrand's disease and angiodysplasia treated with thalidomide. Haemophilia 2006; 12:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/17\">",
"      Drews CD, Dilley AB, Lally C, et al. Screening questions to identify women with von Willebrand disease. J Am Med Womens Assoc 2002; 57:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/18\">",
"      Rodeghiero F, Castaman G, Tosetto A, et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2005; 3:2619.",
"     </a>",
"    </li>",
"    <li>",
"     A monograph detailing this bleeding score is available on the International Society on Thrombosis and Haemostasis website www.med.unc.edu/isth/ssc_home.htm (Accessed on February 05, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/20\">",
"      Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/21\">",
"      Tosetto A, Castaman G, Rodeghiero F. Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. Blood 2008; 111:3998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/22\">",
"      Bowman M, Mundell G, Grabell J, et al. Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease. J Thromb Haemost 2008; 6:2062.",
"     </a>",
"    </li>",
"    <li>",
"     Available on the J Thromb Haemost website www3.interscience.wiley.com/journal/121429621/suppinfo (Accessed on February 05, 2009).",
"    </li>",
"    <li>",
"     The Diagnosis, Evaluation and Management of von Willebrand Disease -- 2008 Clinical Practice Guidelines, National Heart, Lung and Blood Institute www.nhlbi.nih.gov/guidelines/vwd (Accessed on July 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/25\">",
"      Weiss HJ, Pietu G, Rabinowitz R, et al. Heterogeneous abnormalities in the multimeric structure, antigenic properties, and plasma-platelet content of factor VIII/von Willebrand factor in subtypes of classic (type I) and variant (type IIA) von Willebrand's disease. J Lab Clin Med 1983; 101:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/26\">",
"      Zimmerman TS, Ratnoff OD, Powell A. Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand's disease. J Clin Invest 1971; 50:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/27\">",
"      Mazurier C, Parquet-Gernez A, Goudemand M. The assay of Factor VIII related antigen by an immuno-enzymatic method. Thromb Haemost 1980; 43:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/28\">",
"      Ingerslev J. A sensitive ELISA for von Willebrand factor (vWf:Ag). Scand J Clin Lab Invest 1987; 47:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/29\">",
"      Veyradier A, Fressinaud E, Sigaud M, et al. A new automated method for von Willebrand factor antigen measurement using latex particles. Thromb Haemost 1999; 81:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/30\">",
"      Weiss HJ, Hoyer LW, Rickles FR, et al. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. J Clin Invest 1973; 52:2708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/31\">",
"      Howard MA, Sawers RJ, Firkin BG. Ristocetin: a means of differentiating von Willebrand's disease into two groups. Blood 1973; 41:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/32\">",
"      Scott JP, Montgomery RR, Retzinger GS. Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor-dependent agglutination of platelets. J Biol Chem 1991; 266:8149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/33\">",
"      Berndt MC, Du XP, Booth WJ. Ristocetin-dependent reconstitution of binding of von Willebrand factor to purified human platelet membrane glycoprotein Ib-IX complex. Biochemistry 1988; 27:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/34\">",
"      Allain JP, Cooper HA, Wagner RH, Brinkhous KM. Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor. J Lab Clin Med 1975; 85:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/35\">",
"      Ruggeri ZM, Pareti FI, Mannucci PM, et al. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med 1980; 302:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/36\">",
"      Lindahl TL, Fagerberg IH, Larsson A. A new flow cytometric method for measurement of von Willebrand factor activity. Scand J Clin Lab Invest 2003; 63:217.",
"     </a>",
"    </li>",
"    <li>",
"     Strandberg K, Andersson K, Carlson M, et al. Evaluation of an automated assay for rapid analysis of von Willebrand ristocetin cofactor activity (abstract). J Thromb and Haemost 2003; 1 Supp 1: Abstract 1676.",
"    </li>",
"    <li>",
"     Pinol M, Costa M, Sales M, et al. New automated von Willebrand factor activity assay to distinguish type 1 and type 2 von Willebrand disease (VWD) (abstract). J Thromb and Haemost 2003; 1 Supp 1: Abstract 1679.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/39\">",
"      Favaloro EJ, Grispo L, Exner T, Koutts J. Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II, von Willebrand's disease. Blood Coagul Fibrinolysis 1991; 2:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/40\">",
"      Chang P, Aronson DL. Plasma derived von Willebrand factor preparations: collagen binding and ristocetin cofactor activities. Thromb Haemost 1997; 78:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/41\">",
"      Favaloro EJ, Henniker A, Facey D, Hertzberg M. Discrimination of von Willebrands disease (VWD) subtypes: direct comparison of von Willebrand factor:collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based VWF-capture systems. Thromb Haemost 2000; 84:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/42\">",
"      Favaloro EJ, Facey D, Grispo L. Laboratory assessment of von Willebrand factor. Use of different assays can influence the diagnosis of von Willebrand's disease, dependent on differing sensitivity to sample preparation and differential recognition of high molecular weight VWF forms. Am J Clin Pathol 1995; 104:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/43\">",
"      Casonato A, Pontara E, Bertomoro A, et al. Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin co-factor activity? Br J Haematol 2001; 112:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/44\">",
"      Favaloro EJ. Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects. Direct comparison of commercial ELISA-based von Willebrand factor activity options. Am J Clin Pathol 2000; 114:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/45\">",
"      Riddell AF, Jenkins PV, Nitu-Whalley IC, et al. Use of the collagen-binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with the ristocetin cofactor assay. Br J Haematol 2002; 116:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/46\">",
"      Riddell AF, Gomez K, Millar CM, et al. Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor. Blood 2009; 114:3489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/47\">",
"      Cinotti S, Longo G, Messori A, et al. Reproducibility of one-stage, two-stage and chromogenic assays of factor VIII activity: a multi-center study. Thromb Res 1991; 61:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/48\">",
"      Hoyer LW. Immunologic studies of antihemophilic factor (AHF, factor VIII). IV. Radioimmunoassay of AHF antigen. J Lab Clin Med 1972; 80:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/49\">",
"      Flood VH, Gill JC, Morateck PA, et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood 2010; 116:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/50\">",
"      Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/51\">",
"      Fressinaud E, Veyradier A, Truchaud F, et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998; 91:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/52\">",
"      Posan E, McBane RD, Grill DE, et al. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thromb Haemost 2003; 90:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/53\">",
"      Castaman G, Tosetto A, Goodeve A, et al. The impact of bleeding history, von Willebrand factor and PFA-100(&reg;) on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD. Br J Haematol 2010; 151:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/54\">",
"      Quiroga T, Goycoolea M, Mu&ntilde;oz B, et al. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients. J Thromb Haemost 2004; 2:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/55\">",
"      Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/56\">",
"      Ratnoff OD, Saito H. Letter: Bleeding in von Willebrand's disease. N Engl J Med 1974; 290:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/57\">",
"      Gralnick HR, Rick ME, McKeown LP, et al. Platelet von Willebrand factor: an important determinant of the bleeding time in type I von Willebrand's disease. Blood 1986; 68:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/58\">",
"      Peterson P, Hayes TE, Arkin CF, et al. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. Arch Surg 1998; 133:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/59\">",
"      Hoyer LW, Shainoff JR. Factor VIII-related protein circulates in normal human plasma as high molecular weight multimers. Blood 1980; 55:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/60\">",
"      Krizek DR, Rick ME. A rapid method to visualize von willebrand factor multimers by using agarose gel electrophoresis, immunolocalization and luminographic detection. Thromb Res 2000; 97:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/61\">",
"      Weiss HJ, Meyer D, Rabinowitz R, et al. Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers. N Engl J Med 1982; 306:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/62\">",
"      Miller JL, Kupinski JM, Castella A, Ruggeri ZM. von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease. J Clin Invest 1983; 72:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/63\">",
"      Enayat MS, Guilliatt AM, Lester W, et al. Distinguishing between type 2B and pseudo-von Willebrand disease and its clinical importance. Br J Haematol 2006; 133:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/64\">",
"      Scott JP, Montgomery RR. The rapid differentiation of type IIb von Willebrand's disease from platelet-type (pseudo-) von Willebrand's disease by the \"neutral\" monoclonal antibody binding assay. Am J Clin Pathol 1991; 96:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/65\">",
"      L&oacute;pez JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood 1998; 91:4397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/66\">",
"      Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003; 101:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/67\">",
"      Bellissimo DB, Christopherson PA, Flood VH, et al. VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. Blood 2012; 119:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/68\">",
"      Abildgaard CF, Suzuki Z, Harrison J, et al. Serial studies in von Willebrand's disease: variability versus \"variants\". Blood 1980; 56:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/69\">",
"      Gill JC, Endres-Brooks J, Bauer PJ, et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/70\">",
"      O'Donnell J, Boulton FE, Manning RA, Laffan MA. Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level. Br J Haematol 2002; 116:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/71\">",
"      Nitu-Whalley IC, Lee CA, Griffioen A, et al. Type 1 von Willebrand disease - a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol 2000; 108:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/72\">",
"      Baumgartner-Parzer SM, Wagner L, Reining G, et al. Increase by tri-iodothyronine of endothelin-1, fibronectin and von Willebrand factor in cultured endothelial cells. J Endocrinol 1997; 154:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/73\">",
"      Harrison RL, McKee PA. Estrogen stimulates von Willebrand factor production by cultured endothelial cells. Blood 1984; 63:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/74\">",
"      van den Burg PJ, Hospers JE, van Vliet M, et al. Changes in haemostatic factors and activation products after exercise in healthy subjects with different ages. Thromb Haemost 1995; 74:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/75\">",
"      Rickles FR, Hoyer LW, Rick ME, Ahr DJ. The effects of epinephrine infusion in patients with von Willebrand's disease. J Clin Invest 1976; 57:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/76\">",
"      McGill SN, Ahmed NA, Christou NV. Increased plasma von Willebrand factor in the systemic inflammatory response syndrome is derived from generalized endothelial cell activation. Crit Care Med 1998; 26:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/77\">",
"      van der Poll T, van Deventer SJ, Pasterkamp G, et al. Tumor necrosis factor induces von Willebrand factor release in healthy humans. Thromb Haemost 1992; 67:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/78\">",
"      Bennett B, Ratnoff OD. Changes in antihemophilic factor (AHF, factor 8) procoagulant activity and AHF-like antigen in normal pregnancy, and following exercise and pneumoencephalography. J Lab Clin Med 1972; 80:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/79\">",
"      Si&eacute; P, Caron C, Azam J, et al. Reassessment of von Willebrand factor (VWF), VWF propeptide, factor VIII:C and plasminogen activator inhibitors 1 and 2 during normal pregnancy. Br J Haematol 2003; 121:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/80\">",
"      Cumming A, Grundy P, Keeney S, et al. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 2006; 96:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/81\">",
"      Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 109:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/82\">",
"      Schooten CJ, Tjernberg P, Westein E, et al. Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost 2005; 3:2228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/83\">",
"      James PD, Notley C, Hegadorn C, et al. The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. Blood 2007; 109:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/84\">",
"      Haberichter SL, Castaman G, Budde U, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood 2008; 111:4979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/85\">",
"      Castaman G, Lethagen S, Federici AB, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood 2008; 111:3531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/86\">",
"      G&eacute;zsi A, Budde U, De&aacute;k I, et al. Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza. J Thromb Haemost 2010; 8:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/87\">",
"      Lyons SE, Bruck ME, Bowie EJ, Ginsburg D. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem 1992; 267:4424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/88\">",
"      Gralnick HR, Williams SB, McKeown LP, et al. In vitro correction of the abnormal multimeric structure of von Willebrand factor in type IIa von Willebrand's disease. Proc Natl Acad Sci U S A 1985; 82:5968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/89\">",
"      Grainick HR, Williams SB, McKeown LP, et al. Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor. J Clin Invest 1985; 76:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/90\">",
"      Federici AB, Canciani MT, Forza I, et al. A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ibalpha for the diagnosis of patients with low von Willebrand factor levels. Haematologica 2004; 89:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/91\">",
"      Caron C, Hilbert L, Vanhoorelbeke K, et al. Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease. Br J Haematol 2006; 133:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/92\">",
"      Favaloro EJ, Patterson D, Denholm A, et al. Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis. Br J Haematol 2007; 139:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/93\">",
"      Hillery CA, Mancuso DJ, Evan Sadler J, et al. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets. Blood 1998; 91:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/94\">",
"      Ciavarella G, Ciavarella N, Antoncecchi S, et al. High-resolution analysis of von Willebrand factor multimeric composition defines a new variant of type I von Willebrand disease with aberrant structure but presence of all size multimers (type IC). Blood 1985; 66:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/95\">",
"      Lopez-Fernandez MF, Gonzalez-Boullosa R, Blanco-Lopez MJ, et al. Abnormal proteolytic degradation of von Willebrand factor after desmopressin infusion in a new subtype of von Willebrand disease (ID). Am J Hematol 1991; 36:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/96\">",
"      Mannucci PM, Lombardi R, Castaman G, et al. von Willebrand disease \"Vicenza\" with larger-than-normal (supranormal) von Willebrand factor multimers. Blood 1988; 71:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/97\">",
"      Schneppenheim R, Federici AB, Budde U, et al. Von Willebrand Disease type 2M \"Vicenza\" in Italian and German patients: identification of the first candidate mutation (G3864A; R1205H) in 8 families. Thromb Haemost 2000; 83:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/98\">",
"      Kroner PA, Friedman KD, Fahs SA, et al. Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease. J Biol Chem 1991; 266:19146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/99\">",
"      Rick ME, Krizek DM. Identification of a His54Gln substitution in von Willebrand factor from a patient with defective binding of factor VIII. Am J Hematol 1996; 51:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/100\">",
"      Kroner PA, Foster PA, Fahs SA, Montgomery RR. The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor. Blood 1996; 87:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/101\">",
"      Cacheris PM, Nichols WC, Ginsburg D. Molecular characterization of a unique von Willebrand disease variant. A novel mutation affecting von Willebrand factor/factor VIII interaction. J Biol Chem 1991; 266:13499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/102\">",
"      Gaucher C, Mercier B, Jorieux S, et al. Identification of two point mutations in the von Willebrand factor gene of three families with the 'Normandy' variant of von Willebrand disease. Br J Haematol 1991; 78:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/103\">",
"      Eikenboom JC, Castaman G, Kamphuisen PW, et al. The factor VIII/von Willebrand factor ratio discriminates between reduced synthesis and increased clearance of von Willebrand factor. Thromb Haemost 2002; 87:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/104\">",
"      Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000; 111:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/105\">",
"      Ngo KY, Glotz VT, Koziol JA, et al. Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease. Proc Natl Acad Sci U S A 1988; 85:2753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/106\">",
"      Schneppenheim R, Krey S, Bergmann F, et al. Genetic heterogeneity of severe von Willebrand disease type III in the German population. Hum Genet 1994; 94:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/107\">",
"      Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4:2103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/108\">",
"      Lipton R. Why make a diagnosis? Blood 2007; 109:4106; author reply 4106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/109\">",
"      Lipton R. Why make a diagnosis? Blood 2007; 109:4106; author reply 4106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/110\">",
"      Sadler JE. Low von Willebrand factor: sometimes a risk factor and sometimes a disease. Hematology Am Soc Hematol Educ Program 2009; :106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/111\">",
"      Rodeghiero F, Castaman G, Tosetto A. Optimizing treatment of von Willebrand disease by using phenotypic and molecular data. Hematology Am Soc Hematol Educ Program 2009; :113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/13/24794/abstract/112\">",
"      Tiede A, Rand JH, Budde U, et al. How I treat the acquired von Willebrand syndrome. Blood 2011; 117:6777.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1307 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-BE5EBB4FC7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_13_24794=[""].join("\n");
var outline_f24_13_24794=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H712828745\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMPORTANCE OF VON WILLEBRAND FACTOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSTIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Personal and family history and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Screening of family members",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LABORATORY TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      VWF antigen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      VWF activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Collagen binding assay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H623617\">",
"      Factor VIII activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Ratio of VWF activity to VWF antigen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Diagnosis of VWD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Platelet function analyzer assay",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Bleeding time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      VWF multimers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Ristocetin induced platelet aggregation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H624057\">",
"      Variations in VWF levels in health and disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIAGNOSIS (CLASSIFICATION) OF VWD TYPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Type 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Type 2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Type 2A",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Type 2B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Platelet-type VWD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Type 2M",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Type 2N",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Type 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H623769\">",
"      Low VWF versus type 1 VWD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8873047\">",
"      Acquired VWD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H712828745\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H712828753\">",
"      When to suspect von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H712829008\">",
"      Initial testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H712829123\">",
"      Making a diagnosis of VWD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1307\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1307|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/17/7446\" title=\"figure 1\">",
"      Platelet interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/37/34398\" title=\"figure 2\">",
"      VWF mRNA and functional domains",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1307|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/1/15391\" title=\"picture 1\">",
"      VWF multimer analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1307|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/14/5356\" title=\"table 1\">",
"      Classification of VWD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/63/17404\" title=\"table 2\">",
"      Von Willebrand factor assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/36/11851\" title=\"table 3\">",
"      Diagnostic criteria VWD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/62/17388\" title=\"table 4\">",
"      Disorders associated with acquired vWD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8410?source=related_link\">",
"      Angiodysplasia of the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17049?source=related_link\">",
"      Biology and normal function of von Willebrand factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=related_link\">",
"      Classification and pathophysiology of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11160?source=related_link\">",
"      Differential diagnosis and approach to the adolescent with abnormal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/55/6002?source=related_link\">",
"      Patient information: von Willebrand disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/32/39425?source=related_link\">",
"      Patient information: von Willebrand disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=related_link\">",
"      Platelet function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32439?source=related_link\">",
"      Preoperative assessment of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=related_link\">",
"      Terminology and evaluation of abnormal uterine bleeding in premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=related_link\">",
"      Treatment of von Willebrand disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_13_24795="Diagnostic criteria for rheumatic heart disease";
var content_f24_13_24795=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for rheumatic heart disease based on clinical and echocardiographic findings",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Category of rheumatic heart disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Finding on clinical cardiac auscultation (ie, presence of murmur of MR, AR, and/or MS)",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        <p>",
"         Echocardiographic structural and functional changes of MS without murmur (ie, \"silent\" mitral stenosis)",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Echocardiographic valvular structural abnormality (ie, presence of typical rheumatic valve morphology)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Echocardiographic functional abnormality (ie, presence of significant valve regurgitation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Definite",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Probable",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Possible",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Source: WHO Technical Report Series. Rheumatic fever and rheumatic heart disease: Report of a WHO expert panel, Geneva 29 October - 1 November 2001. Geneva: WHO; 2004.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_13_24795=[""].join("\n");
var outline_f24_13_24795=null;
var title_f24_13_24796="Suicide risk assessment1";
var content_f24_13_24796=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suicide risk assessment for children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Content and nature of suicidal ideation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        What are the thoughts?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Are they active (volitional and with intent) or passive/non-volitional?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How often do they occur?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have they increased in intensity or frequency?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How long do they last (duration)? Are they obsessive?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can the thoughts be controlled?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How powerful, intense is the urge?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How do the thoughts make you feel?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Anticipated method/Planning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the child or adolescent have a method in mind? If so, have the adolescent describe it",
"        <strong>",
"         explicitly",
"        </strong>",
"        (since this provides information about the adolescent's level of intent and planning)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Sample questions include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Do you have a plan?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        What time would you do it?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Where would you do it?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Do you think it would work?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Do you think this would kill you?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Is there anyone who could find you and save you?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Access to means",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the adolescent have",
"        <strong>",
"         access",
"        </strong>",
"        to the method they have in mind?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        What is the level of dangerousness or lethality of the means they are considering?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the child or adolescent have access to firearms and medications?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Sample questions include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Do you have any of these things (pills, gun, razor, etc) in your possession?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        How easy would it be for you to get them?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Jacobs, DG, Brewer, M, Klein-Benheim, M. Suicide assessment: An overview and recommended protocol. In: Harvard Medical School Guide to Assessment and Intervention in Suicide, Jacob, D (Ed). Jossey-Bass, San Francisco 1998. p.3.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_13_24796=[""].join("\n");
var outline_f24_13_24796=null;
var title_f24_13_24797="Kidney pain in ADPKD";
var content_f24_13_24797=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F67374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F67374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis and treatment of kidney pain in ADPKD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pain characteristics",
"       </td>",
"       <td class=\"subtitle1\">",
"        Associated features",
"       </td>",
"       <td class=\"subtitle1\">",
"        U/A",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cultures",
"       </td>",
"       <td class=\"subtitle1\">",
"        Imaging",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        <strong>",
"         Cyst hemorrhage",
"        </strong>",
"       </td>",
"       <td>",
"        Sudden onset",
"       </td>",
"       <td>",
"        Usually afebrile",
"       </td>",
"       <td>",
"        +/- Hematuria",
"       </td>",
"       <td rowspan=\"4\">",
"        Negative",
"       </td>",
"       <td rowspan=\"4\">",
"        CT or MRI",
"       </td>",
"       <td>",
"        Analgesics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Localized, unilateral",
"       </td>",
"       <td>",
"        Nausea/vomiting",
"       </td>",
"       <td rowspan=\"3\">",
"        Cultures negative",
"       </td>",
"       <td>",
"        Bed rest and hydration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sharp",
"       </td>",
"       <td rowspan=\"2\">",
"        Hematuria possible",
"       </td>",
"       <td>",
"        Compression on affected side",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Improves after a few days",
"       </td>",
"       <td>",
"        If shock: transfusions",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        <strong>",
"         Pyelonephritis",
"        </strong>",
"       </td>",
"       <td>",
"        Uni/bilateral",
"       </td>",
"       <td>",
"        High grade fever",
"       </td>",
"       <td>",
"        WBCs/pyuria",
"       </td>",
"       <td>",
"        Urine positive",
"       </td>",
"       <td>",
"        Not indicated with positive cultures",
"       </td>",
"       <td rowspan=\"4\">",
"        IV antibiotics with good urine concentration (4 weeks), followed by PO treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progressive",
"       </td>",
"       <td>",
"        Nausea/vomiting",
"       </td>",
"       <td>",
"        +/- Bacteria",
"       </td>",
"       <td rowspan=\"3\">",
"        +/- Positive Blood",
"       </td>",
"       <td rowspan=\"3\">",
"        CT or MRI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Diffuse ++",
"       </td>",
"       <td>",
"        Dysuria",
"       </td>",
"       <td rowspan=\"2\">",
"        +/- Hematuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sepsis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        <strong>",
"         Cyst infection",
"        </strong>",
"       </td>",
"       <td>",
"        Unilateral, localized",
"       </td>",
"       <td>",
"        Fever",
"       </td>",
"       <td rowspan=\"3\">",
"        Usually bland",
"       </td>",
"       <td>",
"        Urine negative",
"       </td>",
"       <td>",
"        CT or MRI",
"       </td>",
"       <td>",
"        Cyst penetrating antibiotics (4 weeks minimum)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subacute",
"       </td>",
"       <td rowspan=\"2\">",
"        Nausea/vomiting",
"       </td>",
"       <td rowspan=\"2\">",
"        Blood positive in 50 percent",
"       </td>",
"       <td rowspan=\"2\">",
"        WBC tagging if uncertain",
"       </td>",
"       <td rowspan=\"2\">",
"        Longer recovery time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sharp ++",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        <strong>",
"         Nephrolithiasis",
"        </strong>",
"       </td>",
"       <td>",
"        Unilateral",
"       </td>",
"       <td>",
"        Usually afebrile unless infection",
"       </td>",
"       <td>",
"        Hematuria common",
"       </td>",
"       <td rowspan=\"5\">",
"        Usually negative unless infected stone",
"       </td>",
"       <td>",
"        Spiral CT",
"       </td>",
"       <td>",
"        IV hydration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute, sharp +++",
"       </td>",
"       <td rowspan=\"4\">",
"        Nausea/vomiting",
"       </td>",
"       <td rowspan=\"4\">",
"        Crystals (uric acid and/or calcium oxalate)",
"       </td>",
"       <td rowspan=\"4\">",
"        Stone protocol",
"       </td>",
"       <td>",
"        Analgesics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paroxysmal",
"       </td>",
"       <td>",
"        Ureteroscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal colic",
"       </td>",
"       <td>",
"        Percutaneous nephrolithotomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiation to pelvis or groin",
"       </td>",
"       <td>",
"        Open surgery",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        <strong>",
"         Chronic cyst/renal pain",
"        </strong>",
"       </td>",
"       <td>",
"        Diffuse",
"       </td>",
"       <td rowspan=\"4\">",
"        Afebrile",
"       </td>",
"       <td>",
"        Chronic hematuria possible",
"       </td>",
"       <td rowspan=\"4\">",
"        Negative",
"       </td>",
"       <td rowspan=\"4\">",
"        Usually negative",
"       </td>",
"       <td>",
"        Analgesics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Constant",
"       </td>",
"       <td rowspan=\"3\">",
"        No WBC",
"       </td>",
"       <td>",
"        Cyst aspiration +/- sclerosis with ethanol or tetracyclines if few large cysts causing pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Variable intensity",
"       </td>",
"       <td>",
"        Cyst reduction surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positional in nature aggravated by inspiration, automobile, sudden impact movements",
"       </td>",
"       <td>",
"        Nephrectomy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Chapman, AB, Rahbari-Oskoui, F. Renal cystic disorders. In: Therapy in nephrology and hypertension, 3rd ed, Wilcox, CS (Ed). Saunders, Philadelphia 2008. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_13_24797=[""].join("\n");
var outline_f24_13_24797=null;
var title_f24_13_24798="Mitral valve vegetation";
var content_f24_13_24798=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/64233/mitral_valve_veget_conv.mp4?title=Mitral+valve+vegetation\" style=\"width:320px;height:244px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral valve vegetation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 319px; height: 228px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dan Sexton, MD. Duke University.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_13_24798=[""].join("\n");
var outline_f24_13_24798=null;
var title_f24_13_24799="Parallel pattern";
var content_f24_13_24799=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dermoscopic structures seen in melanocytic lesions: Parallel pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The parallel pattern is typically seen in palmar and plantar melanocytic lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_13_24799=[""].join("\n");
var outline_f24_13_24799=null;
